{
  "meta": {
    "title": "00252_Mid_Day_Module_Pharma-1",
    "url": "https://brainandscalpel.vercel.app/00252-mid-day-module-pharma-1-c54a4ead.html",
    "scrapedAt": "2025-11-29T18:14:45.480Z"
  },
  "questions": [
    {
      "id": 7157,
      "choices": [
        {
          "id": 28596,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, 3, 4</span></span></span></p>"
        },
        {
          "id": 28597,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2</span></span></span></p>"
        },
        {
          "id": 28598,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3, 4</span></span></span></p>"
        },
        {
          "id": 28599,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, 3</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true regarding memantine? (INICET NOV 2022)</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1. Its therapeutic effect is due to its antagonistic action on NMDA receptors.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2. It is reserved for moderate-to-severe cases of Alzheimer&rsquo;s disease.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3. It is used only as a monotherapy and should not be used with cholinesterase inhibitors.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4. It is given at a daily dose of 20-30 mg/day.</span></span></span></span></p>",
      "unique_key": "Q7074005",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673434,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 1, 2</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1. Its therapeutic effect is due to its antagonistic action on NMDA receptors:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">True. Memantine is an NMDA (N-methyl-D-aspartate) receptor antagonist. It works by blocking the action of glutamate at the NMDA receptors, which is thought to play a role in the symptoms of Alzheimer&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2. It is reserved for moderate-to-severe cases of Alzheimer&rsquo;s disease:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">True. Memantine is typically used in the treatment of moderate to severe Alzheimer&#39;s disease. It is not commonly used in the early stages of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3. It is used only as a monotherapy and should not be used with cholinesterase inhibitors: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">False. Memantine can be used alone (as monotherapy) or in combination with cholinesterase inhibitors, such as donepezil, rivastigmine, or galantamine, in the treatment of Alzheimer&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4. It is given at a daily dose of 20-30 mg/day: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">False. Memantine is started at a lower dose of 5 mg daily and is titrated up to a target dose, which is usually 20 mg/day. Therefore, it is more precise to say that the standard dose is up to 20 mg/day.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Memantine is an NMDA receptor antagonist used for moderate to severe Alzheimer&#39;s disease. It can be used alone or in combination with cholinesterase inhibitors, and the standard maximum dose is 20 mg/day.</span></span></span></p>",
      "correct_choice_id": 28597,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3112,
      "choices": [
        {
          "id": 12431,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CYP 1E6</span></span></span></span></p>"
        },
        {
          "id": 12432,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CYP2D6</span></span></span></span></p>"
        },
        {
          "id": 12433,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CYP2C19</span></span></span></span></p>"
        },
        {
          "id": 12434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CYP 2C9</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The microsomal enzyme involved in the metabolism of clopidogrel, and proton pump inhibitors is?</span></span></span></span></p>",
      "unique_key": "Q4157684",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672791,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) CYP2C19</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>cytochrome P450 </strong>(CYP) <strong>enzymes </strong>are a <strong>family of enzymes </strong>that play a key role in the <strong>metabolism of many drugs</strong>. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is the correct answer. <strong>CYP2C19 </strong>is <strong>involved in the metabolism of clopidogrel </strong>and <strong>PPIs</strong>. <strong>Clopidogrel </strong>is a <strong>prodrug </strong>that <strong>requires activation by this enzyme</strong>, and the <strong>effectiveness of clopidogrel </strong>can be <strong>reduced by PPIs </strong>that <strong>inhibit CYP2C19.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>metabolism of clopidogrel </strong>and <strong>proton pump inhibitors </strong>primarily <strong>involves the CYP2C19 enzyme</strong>, and <strong>inhibitors of this enzyme </strong>can <strong>reduce the activation </strong>and <strong>efficacy of clopidogrel</strong>.</span></span></span></span></p>",
      "correct_choice_id": 12433,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3394,
      "choices": [
        {
          "id": 13555,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug B is the most efficacious</span></span></span></span></p>"
        },
        {
          "id": 13556,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug A and C are equipotent</span></span></span></span></p>"
        },
        {
          "id": 13557,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug B is more efficacious and less potent than drug A</span></span></span></span></p>"
        },
        {
          "id": 13558,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug A and C are Equi efficacious</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Log DRC of four drugs is shown in the given diagram. Which of the following statements is correct about these drugs?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/9.jpg\" style=\"height:346px; width:400px\" /></span></span></span></span></p>",
      "unique_key": "Q4366104",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672804,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Drug A and C are Equi efficacious</span></span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>DRC</strong>, <strong>potency </strong>is assessed by <strong>looking at the location of the curve </strong>on the <strong>X-axis</strong>. <strong>Curves on the right side </strong>are <strong>less potent </strong>and on the <strong>left are more potent</strong>. And efficacy is assessed by the height of the curve on y-axis, higher the curve, more efficacious it is.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug B&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">reaches the <strong>lowest maximum effect</strong>, which means it is the <strong>least efficacious</strong>. However, its <strong>curve starts to rise at the lowest dose</strong>, which indicates it is the most potent.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Drug A and Drug C</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Both these <strong>drugs reach the same maximum effect</strong>, which means they are <strong>equi efficacious</strong>. However, Drug A reaches its half-maximal effect at a lower dose than Drug C, indicating that Drug A is more potent.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The curve for Drug D is <strong>positioned the furthest to the right</strong>, which means it is the <strong>least potent</strong>, as it <strong>requires a higher dose to produce its effect</strong>. However, it reaches the same maximum effect as Drugs A and C, indicating it is equi efficacious to them.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>efficacy of a drug </strong>is determined by the <strong>height of its curve on the y-axis</strong>, and <strong>potency is assessed by the position of the curve along the x-axis</strong>. Drugs A and C are equally efficacious but differ in potency, with Drug A being more potent than Drug C.</span></span></span></span></p>",
      "correct_choice_id": 13558,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7030,
      "choices": [
        {
          "id": 28088,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">1, 3 and 4 are correct</span></p>"
        },
        {
          "id": 28089,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Only 2 is correct</span></p>"
        },
        {
          "id": 28090,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">1 and 2 are correct</span></p>"
        },
        {
          "id": 28091,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">All are correct</span></p>"
        }
      ],
      "text": "<p><span style=\"color:#333333;font-size:12pt;\">Chlorpromazine is an antipsychotic drug. It also produces sedation and adverse effects like dry mouth and hypotension. All these actions result due to action on which of the following receptors?(INICET MAY 2024)</span></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\">1. D2 and 5HT2 receptors</span></p><p><span style=\"color:#333333;font-size:12pt;\">2. GABA and Beta-adrenergic receptors</span></p><p><span style=\"color:#333333;font-size:12pt;\">3. Muscarinic and alpha-adrenergic receptors</span></p><p><span style=\"color:#333333;font-size:12pt;\">4. H1 receptors</span></p>",
      "unique_key": "Q9412442",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673323,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"color:#333333;font-size:12pt;\"><strong>Ans.&nbsp;A. 1, 3 and 4 are correct</strong></span></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\"><strong>Chlorpromazine&nbsp;</strong>is a typical anti-psychotic drug having main mechanism of antipsychotic action as D2 blockade and minor as 5 HT2 blockade. However, it also blocks many other receptors that can result in adverse effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">While chlorpromazine does block H1 receptors causing sedation, it is not the sole receptor responsible for its adverse effects. It must be considered in conjunction with D2, 5HT2, muscarinic, and alpha-adrenergic receptors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Option:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>2. GABA and Beta-adrenergic Receptors:&nbsp;</strong>Chlorpromazine does not primarily act on GABA or beta-adrenergic receptors, hence this option is incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Actions of anti-psychotic drugs</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/17/screenshot-2024-07-17-154713.png\" alt=\"\" width=\"1000\" height=\"352\"></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\"><strong>Reference: - KDT 8<sup>TH</sup>/470-471</strong></span></p>",
      "correct_choice_id": 28088,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6449,
      "choices": [
        {
          "id": 25765,
          "text": "<p><span style=\"font-size:12.0pt;\">It acts as an P2 Y12 agonist</span></p>"
        },
        {
          "id": 25766,
          "text": "<p><span style=\"font-size:12.0pt;\">It is 10 times less potent than clopidogrel</span></p>"
        },
        {
          "id": 25767,
          "text": "<p><span style=\"font-size:12.0pt;\">It is a pro-drug</span></p>"
        },
        {
          "id": 25768,
          "text": "<p><span style=\"font-size:12.0pt;\">Omeprazole interferes with metabolism of prasugrel leading to increased risk of bleeding</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is true about prasugrel?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p>",
      "unique_key": "Q9500420",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673330,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) It is a pro-drug</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Prasugrel is a prodrug that is metabolized by the liver to its active metabolite, which is an inhibitor of P2Y12 ADP platelet receptors. This active metabolite irreversibly inhibits platelet aggregation, making prasugrel a potent antiplatelet agent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A.</strong></span><span style=\"font-size:10.5pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>It acts as an P2 Y12 agonist: It acts as an P2 Y12 agonist</strong> is incorrect because prasugrel is not a P2Y12 agonist but rather an inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B</strong></span><span style=\"font-size:10.5pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>It is 10 times less potent than clopidogrel: </strong>It is 10 times less potent than clopidogrel is incorrect because prasugrel is actually more potent than clopidogrel.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Omeprazole interferes with metabolism of prasugrel leading to increased risk of bleeding: </strong>Omeprazole interferes with metabolism of prasugrel leading to increased risk of bleeding is incorrect because omeprazole can interfere with the activation of prasugrel to its active metabolite, reducing its antiplatelet effect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Prasugrel is a pro-drug that, upon hepatic metabolism, becomes an active metabolite that irreversibly inhibits the P2Y12 ADP platelet receptors, thus preventing platelet aggregation and making it a potent antiplatelet agent.</span></p>",
      "correct_choice_id": 25767,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7159,
      "choices": [
        {
          "id": 28604,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raltegravir</span></span></span></span></span></p>"
        },
        {
          "id": 28605,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Enfuvirtide</span></span></span></span></span></p>"
        },
        {
          "id": 28606,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Tenofovir</span></span></span></span></span></p>"
        },
        {
          "id": 28607,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Zidovudine</span></span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image below shows the life cycle of human immunodeficiency virus. Which of the following drugs acts at step 5? (INICET NOV 2022)</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/752.jpg\" style=\"height:262px; width:300px\" /></span></span></span></span></span></p>",
      "unique_key": "Q1043661",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673435,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A.&nbsp;</span></span></strong></span><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raltegravir</span></span></strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The step 5 in the given image shows the step of integration of the viral genome into the host DNA with the help of Integrase enzyme. Among the above given drugs, Raltegravir can be used to block this step as it is an integrase inhibitor.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/8.jpg\" style=\"height:491px; width:600px\" /></span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Enfuvirtide:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is fusion inhibitor, which acts by binding to gp41 protein on the surface of the virus. This inhibits the Step 1 of this diagram.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tenofovir &amp; Option D) Zidovudine</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: These are NRTIs which are used in combination therapy against HIV virus. NRTI works by inhibiting the activity of reverse transcriptase (Step 6 of the diagram), thereby, preventing the viral replication.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>",
      "correct_choice_id": 28604,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65741,
      "choices": [
        {
          "id": 262129,
          "text": "<p><span style=\"font-size:12.0pt;\">Atorvastatin</span></p>"
        },
        {
          "id": 262130,
          "text": "<p><span style=\"font-size:12.0pt;\">Fenofibrate</span></p>"
        },
        {
          "id": 262131,
          "text": "<p><span style=\"font-size:12.0pt;\">Nicotinamide</span></p>"
        },
        {
          "id": 262132,
          "text": "<p><span style=\"font-size:12.0pt;\">Ezetimibe</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient being treated for hyperlipidemia developed myopathy, mild hyperglycemia, and raised liver enzymes. Which drug is the most likely cause? <i>(Twisted PYQ)</i></span></p>",
      "unique_key": "Q9616671",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673326,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. &nbsp;A) Atorvastatin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Atorvastatin, a statin, is a lipid-lowering agent used in the management of hyperlipidemia. Statins are commonly associated with side effects such as myopathy (muscle pain, weakness, or elevated creatine kinase), mild hyperglycemia, and hepatotoxicity (manifested as raised liver enzymes). These side effects are particularly important to monitor in patients on statin therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Fenofibrate:</strong> Incorrect because, while it may cause elevated liver enzymes and rarely myopathy (especially when combined with statins), it is not as strongly associated with hyperglycemia or myopathy as statins are.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Nicotinamide:</strong> Incorrect because although nicotinamide (niacin) is associated with hyperglycemia and raised liver enzymes, its hallmark side effects include flushing and gout, not myopathy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Ezetimibe:</strong> Incorrect because it is generally well tolerated and is not associated with myopathy, hyperglycemia, or hepatotoxicity to the extent seen with statins.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Atorvastatin, like other statins, is commonly associated with myopathy, mild hyperglycemia, and hepatotoxicity, making it the most likely cause in this clinical scenario. Monitoring liver enzymes and muscle symptoms is crucial during statin therapy.</span></p>",
      "correct_choice_id": 262129,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56120,
      "choices": [
        {
          "id": 223905,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ionotropic receptor</span></span></span></span></p>"
        },
        {
          "id": 223906,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G-protein-coupled receptor (GPCR)</span></span></span></span></p>"
        },
        {
          "id": 223907,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enzymatic receptor</span></span></span></span></p>"
        },
        {
          "id": 223908,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intracellular receptor</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 62-year-old male presents to the clinic with symptoms of overactive bladder, including frequent urination, urgency, and incontinence. His physician prescribes vibegron to help manage these symptoms. Which of the following best describes the type of receptor that vibegron primarily acts on?</span></span></span></p>",
      "unique_key": "Q8458741",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672800,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. B) G-protein-coupled receptor (GPCR)</span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Vibegron is a selective &beta;3-adrenergic receptor agonist. &beta;3-adrenergic receptors are a type of G-protein-coupled receptor (GPCR). Activation of these receptors in the bladder smooth muscle leads to relaxation, which helps alleviate symptoms of overactive bladder.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Other Options: </span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option A. Ionotropic receptor:</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;Ionotropic receptors are ligand-gated ion channels that open to allow the flow of ions across the membrane when a ligand binds. Vibegron does not act on ionotropic receptors.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option C. Enzymatic receptor:</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;Enzymatic receptors, such as receptor tyrosine kinases, are involved in the activation of intracellular enzymatic activity upon ligand binding. Vibegron does not interact with this type of receptor.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D.&nbsp; Intracellular receptor:</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;Intracellular receptors are typically involved in the action of steroid hormones and other lipophilic substances that enter the cell. Vibegron does not act on intracellular receptors.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Educational Objective:</span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Recognize that vibegron, a treatment for overactive bladder, targets the &beta;3-adrenergic receptor, which is a type of G-protein-coupled receptor (GPCR). Understanding the type of receptor involved helps in comprehending the mechanism of action and therapeutic effects of the drug.</span></span></span></span></span></p>",
      "correct_choice_id": 223906,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3372,
      "choices": [
        {
          "id": 13467,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isoniazid</span></span></span></span></p>"
        },
        {
          "id": 13468,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide</span></span></span></span></p>"
        },
        {
          "id": 13469,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine</span></span></span></span></p>"
        },
        {
          "id": 13470,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amphetamine</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman presents to the clinic with symptoms of a malar rash, joint pain, and fatigue. She has no significant past medical history and reports that she started taking a medication for her recent diagnosis of tuberculosis. Additionally, she has been using an over-the-counter medication for occasional nasal congestion. She denies using any herbal supplements or illicit drugs. Her laboratory tests show positive antinuclear antibodies (ANA) and anti-histone antibodies. Which of the following drugs is not associated with causation of Drug induced lupus?</span></span></span></span></p>",
      "unique_key": "Q1519918",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672792,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Amphetamine</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><strong>Option D:</strong></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lupus syndrome:</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug induced <strong>Lupus Erythematosus </strong>(DILE) is a <strong>variant of lupus erythematosus </strong>that <strong>resolves within days to months </strong>after <strong>withdrawal of the culprit drug </strong>in a patient with no underlying immune system dysfunction.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Isoniazid </strong>is an <strong>antitubercular medication </strong>that is known to <strong>cause drug-induced lupus erythematosus </strong>(DILE).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Procainamide</strong>, an <strong>antiarrhythmic agent</strong>, and <strong>hydralazine</strong>, an <strong>antihypertensive medication</strong>, are both well-documented causes of DILE.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amphetamines </strong>are <strong>central nervous system stimulants </strong>and are <strong>not </strong>typically <strong>associated with the induction of lupus</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amphetamine </strong>is <strong>not </strong>associated with the <strong>causation of drug-induced lupus</strong>, in contrast to certain <strong>drugs like isoniazid, procainamide, </strong>and <strong>hydralazine</strong>, which are known to precipitate DILE.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common drugs that precipitate a DILE or systemic lupus erythematosus like syndrome, including: </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S: S</span></span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ulfonamides</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">H: H</span></span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ydralazine</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">I: I</span></span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">soniazid</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P: P</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">rocainamide</span></span></span></span></p>",
      "correct_choice_id": 13470,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44829,
      "choices": [
        {
          "id": 178963,
          "text": "<p><span style=\"font-size:12pt;\">Evolocumab</span></p>"
        },
        {
          "id": 178964,
          "text": "<p><span style=\"font-size:12pt;\">Ezetimibe</span></p>"
        },
        {
          "id": 178965,
          "text": "<p><span style=\"font-size:12pt;\">Evinacumab</span></p>"
        },
        {
          "id": 178966,
          "text": "<p><span style=\"font-size:12pt;\">Everolimus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following is a PCSK-9 inhibtior? (</span>INICET May 2024)</p>",
      "unique_key": "Q4341520",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673325,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. A) Evolocumab</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:16px;\">Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK-9). By inhibiting PCSK-9, evolocumab increases the number of low-density lipoprotein (LDL) receptors available on the surface of liver cells, thereby reducing LDL cholesterol levels in the blood. It is used for the treatment of hypercholesterolemia.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option</strong>&nbsp;<strong>B.</strong>&nbsp;<strong>Ezetimibe</strong>:&nbsp;Ezetimibe is a cholesterol absorption inhibitor that works by reducing the absorption of cholesterol in the small intestine. It is used to lower LDL cholesterol levels but is not a PCSK-9 inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option</strong>&nbsp;<strong>C.</strong>&nbsp;<strong>Evinacumab</strong>:&nbsp;Evinacumab is a monoclonal antibody that inhibits angiopoietin-like protein 3 (ANGPTL3), which reduces levels of triglycerides, LDL cholesterol, and other lipids. It is used for treating homozygous familial hypercholesterolemia but is not a PCSK-9 inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option</strong>&nbsp;<strong>D.</strong>&nbsp;<strong>Everolimus</strong>:&nbsp;Everolimus is an mTOR inhibitor used primarily as an immunosuppressant in transplant patients and in certain types of cancer. It is not related to cholesterol metabolism and is not a PCSK-9 inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">In summary, evolocumab is the correct answer as it is a PCSK-9 inhibitor used to lower LDL cholesterol levels.</span></p>",
      "correct_choice_id": 178963,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57296,
      "choices": [
        {
          "id": 228561,
          "text": "<p><span style=\"font-size:12.0pt;\">BAL (British Anti-Lewisite)</span></p>"
        },
        {
          "id": 228562,
          "text": "<p><span style=\"font-size:12.0pt;\">EDTA</span></p>"
        },
        {
          "id": 228563,
          "text": "<p><span style=\"font-size:12.0pt;\">DTPA</span></p>"
        },
        {
          "id": 228564,
          "text": "<p><span style=\"font-size:12.0pt;\">Desferrioxamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following chelating agents is contraindicated in iron poisoning? (NEET PG 2024)</span></p>",
      "unique_key": "Q3151992",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673321,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) BAL (British Anti-Lewisite)</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">BAL (British Anti-Lewisite), also known as dimercaprol, is contraindicated in cases of iron poisoning.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">BAL should not be used in this case because it can form toxic complexes with iron, exacerbating the condition rather than alleviating it.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. EDTA:</strong> EDTA is a chelating agent used primarily for lead and other heavy metals, but it is not contraindicated in iron poisoning. However, it is not the preferred chelating agent for iron poisoning either.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. DTPA:</strong> DTPA (Diethylenetriamine pentaacetic acid) is another chelating agent used for certain radioactive heavy metals and is not specifically contraindicated in iron poisoning, although it is not used for iron either.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Desferrioxamine:</strong> Desferrioxamine is the chelating agent of choice in iron poisoning. It binds to free iron and forms a complex that is excreted in the urine, making it effective in reducing iron levels in cases of acute iron toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">BAL (British Anti-Lewisite) is contraindicated in Cadmium and Iron poisoning.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Desferrioxamine is the appropriate chelating agent to use in cases of iron poisoning.</span></p>",
      "correct_choice_id": 228561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3427,
      "choices": [
        {
          "id": 13687,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-4, B-5, C-3, D-2</span></span></span></span></p>"
        },
        {
          "id": 13688,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-4, B-1, C-5, D-3</span></span></span></span></p>"
        },
        {
          "id": 13689,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-2, B-4, C-3, D-5</span></span></span></span></p>"
        },
        {
          "id": 13690,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-4, B-1, C-3, D-5</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following drugs/ligands with their appropriate transmembrane signaling mechanisms as shown in the image?</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/21.jpg\" style=\"height:243px; width:500px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-181327.png\" style=\"height:272px; width:600px\" /></span></span></span></span></p>",
      "unique_key": "Q2618794",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672808,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) A-4, B-1, C-3, D-5</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image depicts various <strong>types of transmembrane signaling mechanisms</strong> used by <strong>different ligands or drugs. </strong>Each mechanism is associated with a specific pathway and type of receptor:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Epinephrine</strong> acts <strong>primarily via G-protein coupled receptors </strong>(GPCRs), as indicated by <strong>label 5 in the image</strong>. These receptors activate intracellular G-proteins, which then modulate the production of second messengers like cAMP.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Barbiturates</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Barbiturates bind</strong> to and <strong>modulate the GABA-A receptor, </strong>which is an<strong> ionotropic receptor</strong> (as indicated by label 4 in the image). This type of <strong>receptor allows for the influx of chloride ions</strong> into the <strong>neuron when activated, </strong>leading to hyperpolarization and decreased neuron excitability.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Aldosterone</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aldosterone interacts </strong>with <strong>intracellular nuclear hormone receptors</strong> (as indicated by label 1 in the image). As a steroid hormone, it is lipid-soluble and can cross the cell membrane to directly regulate gene expression.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Insulin</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Insulin</strong> acts through <strong>enzymatic receptors </strong>that have <strong>intrinsic tyrosine kinase activity</strong> (as indicated by label 3 in the image). Upon binding insulin, these receptors autophosphorylate and initiate a cascade of downstream signaling events.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Barbiturates (A) correspond to 4 (ionotropic receptors).</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aldosterone (B) corresponds to 1 (intracellular receptors).</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin (C) corresponds to 3 (enzymatic receptors with intrinsic tyrosine kinase activity).</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epinephrine (D) corresponds to 5 (G-protein coupled receptors).</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 13690,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3119,
      "choices": [
        {
          "id": 12457,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schedule H drugs</span></span></span></span></p>"
        },
        {
          "id": 12458,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schedule X drugs</span></span></span></span></p>"
        },
        {
          "id": 12459,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schedule J drugs</span></span></span></span></p>"
        },
        {
          "id": 12460,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schedule Y drugs</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs should be sold only on prescription of a registered medical practitioner?</span></span></span></span></p>",
      "unique_key": "Q1327131",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672794,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Schedule H drugs</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">According to the <strong>drugs and cosmetic act, 1940 </strong>(rules 1945), <strong>schedule H deals with the drugs </strong>which must be <strong>sold by retail only </strong>when a <strong>prescription by registered medical practitioner </strong>is <strong>produced</strong>. Most of the drugs fall under this schedule.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Schedule X </strong>gives the <strong>names of psychotropic drugs </strong>requiring <strong>special licenses </strong>for <strong>manufacturing and sale</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Schedule J </strong>deals with a <strong>list of ailments </strong>for which <strong>no drugs claim prevention </strong>or cure.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Schedule Y </strong>specifies <strong>requirements and guidelines on clinical trials</strong>, import and manufacture of new drugs.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Schedule H drugs</strong>, as defined by the <strong>Drugs and Cosmetics Act</strong>, <strong>1940 and Rules</strong>, <strong>1945</strong>, are <strong>medications that require a prescription </strong>from a <strong>registered medical practitioner </strong>for their <strong>sale due to potential risk of misuse </strong>and <strong>safety concerns</strong>.</span></span></span></span></p>",
      "correct_choice_id": 12457,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56124,
      "choices": [
        {
          "id": 223921,
          "text": "<p><span style=\"color:black;font-size:16px;\">A drug is contraindicated in pregnancy if it crosses the placenta.</span></p>"
        },
        {
          "id": 223922,
          "text": "<p><span style=\"color:black;font-size:16px;\">Maximum teratogenic effects are likely in the first trimester.</span></p>"
        },
        {
          "id": 223923,
          "text": "<p><span style=\"color:black;font-size:16px;\">Teratogenicity depends on the dose and duration of therapy.</span></p>"
        },
        {
          "id": 223924,
          "text": "<p><span style=\"color:black;font-size:16px;\">Thalidomide teratogenicity occurs due to binding to cereblon.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A 28-year-old pregnant woman in her first trimester visits her obstetrician for a routine check-up. She has a history of epilepsy and is currently taking antiepileptic medication. She expresses concern about the potential effects of the medication on her developing baby. The obstetrician discusses the risks of drug use during pregnancy, including the concepts of teratogenicity and placental transfer. Which of the following statements about drug use during pregnancy is&nbsp;incorrect?</span></p>",
      "unique_key": "Q8115726",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672801,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ans. A) A drug is contraindicated in pregnancy if it crosses the placenta.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">This statement is incorrect because the fact that a drug crosses the placenta does not automatically mean it is contraindicated in pregnancy. Many drugs cross the placenta but are still used in pregnancy when the benefits outweigh the risks. The decision to use a drug during pregnancy is based on the specific effects on the fetus, the risk-benefit ratio, and the timing of exposure.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option B. Maximum teratogenic effects are likely in the first trimester:</strong>&nbsp;This is correct because the first trimester is the critical period of organogenesis, during which the fetus is most vulnerable to teratogenic effects.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option C. Teratogenicity depends on the dose and duration of therapy:</strong>&nbsp;This statement is correct because the risk of teratogenicity can be influenced by the dose of the drug and the length of time the drug is taken, in addition to other factors like timing during pregnancy.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option D. Thalidomide teratogenicity occurs due to binding to cereblon:</strong>&nbsp;This statement is correct. Thalidomide's teratogenic effects are mediated through its binding to cereblon, a protein that plays a role in limb development and other processes during embryogenesis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Understand that while the first trimester is the period of maximum vulnerability to teratogenic effects, not all drugs that cross the placenta are contraindicated during pregnancy. The decision to use a drug in pregnancy involves a careful evaluation of the risk-benefit ratio. Additionally, recognize that specific mechanisms, such as cereblon binding in the case of thalidomide, can be responsible for a drug's teratogenicity.</span></p>",
      "correct_choice_id": 223921,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13839,
      "choices": [
        {
          "id": 55317,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administration of a bronchodilator drug by inhaled aerosol is usually associated with more adverse effects than administration of this drug by mouth</span></span></span></span></p>"
        },
        {
          "id": 55318,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bioavailability of most drugs is greater with rectal administration than with sublingual administration</span></span></span></span></p>"
        },
        {
          "id": 55319,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administration of a drug by transdermal patch is often faster but is associated with more first pass metabolism than oral administration</span></span></span></span></p>"
        },
        {
          "id": 55320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient, Rajesh with a history of wheezing, coughing and shortness of breath is being evaluated in the asthma clinic. Several drug treatments with different routes are under consideration. Which of the following statements about routes of administration is most correct?</span></span></span></span></p>",
      "unique_key": "Q4399625",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672784,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> first-pass effect </strong>is the <strong>elimination of a drug</strong> that occurs after <strong>administration</strong> but <strong>before it enters</strong> the<strong> systemic circulation, </strong>usually <strong>due to metabolism by the liver enzymes</strong> present in the<strong> hepatic portal circulation.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is <strong>incorrect</strong> because<strong> inhaled aerosol administration </strong>of bronchodilator drugs is associated with <strong>fewer adverse effects </strong>than <strong>oral administration</strong>, as it<strong> allows for targeted delivery of the drug</strong> to the<strong> site of action in the lungs,</strong> with <strong>minimal systemic</strong> <strong>absorption.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is <strong>incorrect</strong> because <strong>sublingual administration</strong> generally results in<strong> greater bioavailability </strong>than <strong>rectal administration,</strong> as the <strong>sublingual route</strong> allows for<strong> rapid absorption of the drug </strong>into the<strong> bloodstream</strong> through the <strong>rich network of blood vessels</strong> under the <strong>tongue</strong>, <strong>bypassing</strong> the <strong>first-pass metabolism in the liver.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is<strong> incorrect</strong> because<strong> transdermal administration </strong>of a drug is associated with <strong>slower onset of action </strong>than<strong> oral</strong> <strong>administration, </strong>as the<strong> drug</strong> must <strong>penetrate the skin</strong> barrier to<strong> enter systemic circulation.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>First pass effect</strong> refers to the<strong> metabolism of a drug </strong>within the<strong> liver</strong> that significantly <strong>reduces </strong>the <strong>bioavailability of the drug before</strong> it reaches<strong> systemic circulation</strong>, as opposed to<strong> comparing routes of administration</strong> and <strong>their impact </strong>on <strong>drug delivery</strong> and <strong>metabolism.</strong></span></span></span></span></p>",
      "correct_choice_id": 55320,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 58784,
      "choices": [
        {
          "id": 234469,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AUC </span></span></span></span></p>"
        },
        {
          "id": 234470,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T1/2</span></span></span></span></p>"
        },
        {
          "id": 234471,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cmax </span></span></span></span></p>"
        },
        {
          "id": 234472,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tmax</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old male patient is being treated for chronic neuropathic pain with an oral medication. The healthcare team monitors the drug&#39;s plasma concentration over time. Which parameter on the plasma concentration vs. time graph helps to guide dose adjustments to maximize efficacy without causing toxicity?&nbsp;</span></span></p>",
      "unique_key": "Q8041099",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672787,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Cmax</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The parameter that best helps guide dose adjustments to maximize efficacy without causing toxicity on a plasma concentration vs. time graph is&nbsp;<strong>Cmax (Maximum Concentration)</strong>.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cmax</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;represents the peak concentration of the drug in the plasma after administration. This parameter is crucial in understanding both the therapeutic and toxic potential of the drug. For medications with a narrow therapeutic index, where small changes in drug levels can lead to toxicity, monitoring Cmax helps ensure that the concentration stays within the desired therapeutic window. If Cmax exceeds this window, dose adjustments are necessary to avoid adverse effects. Conversely, if Cmax is too low, the drug may not provide the desired therapeutic effect, leading to dose increases.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. AUC (Area Under the Curve): AUC</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;represents the total drug exposure over time and gives an indication of how much drug has been absorbed into the bloodstream. While it&rsquo;s useful for understanding the overall exposure, it does not give direct information about the peak plasma concentration, which is critical for determining potential toxicity and efficacy. AUC is more relevant for evaluating the bioavailability of the drug.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Optyion B. T1/2 (Half-life): T1/2</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, or half-life, refers to the time it takes for the plasma concentration of a drug to reduce by half. It is important for determining how frequently a drug should be administered (dosing intervals), but it does not directly help in assessing the peak concentration or adjusting doses for efficacy and safety. It is more useful for understanding drug clearance and duration of action.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Tmax (Time to Maximum Concentration): Tmax</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;is the time at which the maximum plasma concentration (Cmax) is reached. While it tells you when the peak concentration occurs, it does not provide information about the magnitude of the peak concentration, which is necessary to make dosing adjustments. Tmax is useful for determining the absorption rate of a drug but is less directly related to toxicity and efficacy adjustments.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Important points about the PC-T graph:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cmax</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;helps assess peak drug levels for efficacy and toxicity.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tmax</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;indicates the rate of absorption.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AUC</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;tells about extent of drug absorption.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T1/2</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;helps determine dosing intervals.</span></span></span></span></li>\r\n</ol>",
      "correct_choice_id": 234471,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3390,
      "choices": [
        {
          "id": 13539,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14px;\">Glucocorticoids</span></p>"
        },
        {
          "id": 13540,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14px;\">Estrogen</span></p>"
        },
        {
          "id": 13541,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14px;\">Propranolol</span></p>"
        },
        {
          "id": 13542,
          "text": "<p><span style=\"font-size:14px;\">Nicotine</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14px;\">A 59-year-old man with a history of chronic obstructive pulmonary disease (COPD) and hypertension is being managed in an outpatient clinic. He has been prescribed a nonselective beta-blocker to manage his hypertension. Based on the receptor shown in the figure, which of the following drugs prescribed to the patient acts through this type of receptor?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:black;font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/7_ybtpG0K.jpg\" alt=\"\" width=\"500\" height=\"387\"></span></p>",
      "unique_key": "Q8891905",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672802,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><strong>Ans. C) Propranolol</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><strong>Option C</strong>:</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:14px;\">Figure shows the <strong>presence of heptahelical transmembrane receptors </strong>which <strong>corresponds to G-protein coupled receptors</strong>.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><strong>Propranolol </strong>is a <strong>beta-blocker </strong>that <strong>acts via G-protein coupled receptors </strong>(GPCRs), which are <strong>heptahelical transmembrane receptors</strong>, as shown in the figure.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:14px;\"><strong>Option A.</strong> <strong>Glucocorticoids:&nbsp;</strong>Act through <strong>cytoplasmic receptors </strong>that, <strong>upon activation</strong>, <strong>translocate to the nucleus </strong>to <strong>affect gene transcription</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><strong>Option B.</strong> <strong>Estrogen: Binds to nuclear receptors </strong>which <strong>directly interact with DNA to regulate gene expression</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><strong>Option D</strong>. <strong>Nicotine:&nbsp;</strong>Primarily acts through <strong>nicotinic acetylcholine receptors</strong>, which are <strong>ionotropic receptors, </strong>not GPCRs.</span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><strong><u>Educational Objective</u></strong><u>:</u></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><strong>Propranolol acts via G-protein coupled receptors</strong>, which are characterized by their <strong>seven-transmembrane domain structure</strong>.</span></p>",
      "correct_choice_id": 13541,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3367,
      "choices": [
        {
          "id": 13447,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase I </span></span></span></span></p>"
        },
        {
          "id": 13448,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase II</span></span></span></span></p>"
        },
        {
          "id": 13449,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase III </span></span></span></span></p>"
        },
        {
          "id": 13450,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase IV</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A newly approved drug has just been released onto the market for widespread use. What phase of clinical trials includes the ongoing observation for rare and long-term adverse effects after a drug is commercially available? </span></span></p>",
      "unique_key": "Q2881900",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672790,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Phase IV</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase IV trials</strong>, also known as <strong>post-marketing surveillance</strong>, <strong>monitor the safety of a drug </strong>after it has been <strong>released on the market</strong>, looking specifically for <strong>rare and long-term adverse effects </strong>in a <strong>larger</strong>, <strong>more diverse population</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase I</strong>: Incorrect. Phase I trials are <strong>initial safety trials conducted on a small group </strong>of healthy volunteers or patients.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase II</strong>: Incorrect. Phase II trials are <strong>conducted to assess the drug&#39;s efficacy </strong>and side effects in a larger group of people.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase III</strong>: Incorrect. Phase III trials are <strong>larger studies that confirm a drug&rsquo;s effectiveness</strong>, monitor side effects, and compare it to commonly used treatments.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase IV clinical trials</strong>, or <strong>post-marketing surveillance, </strong>are <strong>conducted after a drug is approved </strong>and <strong>marketed to monitor for rare </strong>and <strong>long-term adverse effects </strong>and to ensure ongoing evaluation of the drug&#39;s risk-benefit profile in the general population.</span></span></span></span></p>",
      "correct_choice_id": 13450,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3101,
      "choices": [
        {
          "id": 12387,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B is competitive and C is non-competitive antagonist</span></span></span></span></p>"
        },
        {
          "id": 12388,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B is non-competitive an C is competitive antagonist</span></span></span></span></p>"
        },
        {
          "id": 12389,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both are competitive antagonists</span></span></span></span></p>"
        },
        {
          "id": 12390,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both are non-competitive antagonists</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given image shows the Log DRC of a drug alone (A) and in the presence of antagonists (B and C). Identify the type of antagonism shown in curve B and curve C?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/11.jpg\" style=\"height:293px; width:400px\" /></span></span></span></span></p>",
      "unique_key": "Q3723770",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672786,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) B is competitive, and C is non competitive antagonist</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image provided shows <strong>two dose-response curves</strong> (DRCs) in the <strong>presence of antagonists compared to the drug given alone</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Curve A</strong> represents the <strong>log dose-response of the drug alone</strong>.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Curve B </strong>shows a <strong>rightward shift of the DRC without a change in the maximal response</strong>, which is characteristic of competitive antagonism. A competitive antagonist binds reversibly to the same active site as the agonist, requiring higher concentrations of the agonist to achieve the same effect, thus reducing its potency but not its maximal efficacy.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Curve C shows a decreased maximal response</strong> <strong>without </strong>a significant <strong>shift in the position of the curve along the dose axis,</strong> which is <strong>typical for non-competitive antagonism.</strong> Non-competitive antagonists bind to a site different from the agonist and can reduce the maximum effect that the agonist can produce, thereby reducing efficacy but not necessarily changing the potency.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thus option A: B is competitive and C is non-competitive antagonist</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is <strong>correct</strong>. <strong>Curve B</strong> shows a <strong>shift to the right without a change in maximal efficacy</strong> (competitive antagonism), and <strong>curve C </strong>shows a <strong>decreased maximal response</strong> (non-competitive antagonism).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On a <strong>dose-response curve</strong>, <strong>competitive antagonism</strong> is characterized by a <strong>rightward shift of the curve with no change in maximal response,</strong> whereas <strong>non-competitive antagonism</strong> results in a <strong>decrease in maximal response</strong> without a significant shift in potency.</span></span></span></span></p>",
      "correct_choice_id": 12387,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3067,
      "choices": [
        {
          "id": 12253,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspirin</span></span></span></span></p>"
        },
        {
          "id": 12254,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate</span></span></span></span></p>"
        },
        {
          "id": 12255,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphine</span></span></span></span></p>"
        },
        {
          "id": 12256,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenobarbitone</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old male is brought to the emergency department after ingesting an overdose of a medication. In order to enhance drug clearance, you consider the modification of urinary pH as a therapeutic measure. Knowing that manipulating the urinary pH can increase the excretion of certain drugs by altering their ionization state, which of the following drugs would not have its excretion increased by alkalinization of the urine?</span></span></span></span></p>",
      "unique_key": "Q8560066",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672812,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Morphine </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Morphine </strong>is a <strong>basic drug</strong>. <strong>Alkalizing the urine </strong>would actually <strong>decrease its excretion </strong>because it would be <strong>less ionized </strong>and <strong>more readily reabsorbed in the renal tubules</strong>. <strong>Acidifying the urine </strong>would <strong>increase morphine excretion</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aspirin</strong>: <strong>Aspirin </strong>(acetylsalicylic acid) is an <strong>acidic drug</strong>. Alkalinizing the urine with agents such as sodium bicarbonate can enhance its ionization and excretion.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Methotrexate</strong>: This is also an <strong>acidic drug</strong>, and <strong>alkalinization of the urine will increase its ionization</strong>, decreasing reabsorption and increasing elimination.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phenobarbitone</strong>: This is an <strong>acidic drug</strong>, and like <strong>aspirin and methotrexate</strong>, it is more ionized in alkaline urine, leading to increased excretion.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cases of <strong>drug overdose</strong>, <strong>urinary alkalinization </strong>is utilized to <strong>increase the excretion of acidic drugs </strong>by <strong>enhancing their ionization</strong>, which does not apply to basic drugs like morphine that are better excreted in acidic conditions. Remember, the drugs ending with &lsquo;ine&rsquo; are basic.</span></span></span></span></p>",
      "correct_choice_id": 12255,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3382,
      "choices": [
        {
          "id": 13507,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">150 mg</span></span></span></span></p>"
        },
        {
          "id": 13508,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2.5 mg</span></span></span></span></p>"
        },
        {
          "id": 13509,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">24 mg</span></span></span></span></p>"
        },
        {
          "id": 13510,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10 mg</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male patient (60 kg) is going to be treated with an experimental drug, Drug X, for an irregular heart rhythm. If the Vd is 1 L/kg and the desired steady state plasma concentration is 2.5 mg/L, which of the following is the most appropriate intravenous loading dose for Drug X? </span></span></span></span></p>",
      "unique_key": "Q3597735",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672799,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 150 mg</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12px\"><strong>Option A:</strong></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For IV infusion, Loading dose = (V<sub>d</sub>) &times; (desired steady-state plasma concentration). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The V<sub>d</sub> in this case is 1 L/kg, so for a 60 Kg person, Vd is 60 L. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thus, Loading dose = 60 L &times; 2.5 mg/L = 150 mg</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct <strong>intravenous loading dose </strong>of a <strong>drug can be calculated by multiplying the volume </strong>of <strong>distribution by the desired plasma concentration</strong>; in this case, <strong>60 L &times; 2.5 mg/L = 150 mg</strong>.</span></span></span></span></p>",
      "correct_choice_id": 13507,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3107,
      "choices": [
        {
          "id": 12411,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Its Cmax is 20 &mu;g/dl</span></span></span></span></p>"
        },
        {
          "id": 12412,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AUC from the above graph reflects the rate of absorption of the drug</span></span></span></span></p>"
        },
        {
          "id": 12413,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tmax for drug X is 7 hours</span></span></span></span></p>"
        },
        {
          "id": 12414,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Instead of 100 mg drug X should be given in divided doses</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A new drug X is given orally to a healthy volunteer in a dose of 100 mg. Plasma concentration of the drug is measured at hourly intervals and a graph is plotted between plasma concentration and time as shown below in Fig. Which of the following statements about drug X is TRUE?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/12.jpg\" style=\"height:228px; width:400px\" /></span></span></span></span></p>",
      "unique_key": "Q5697871",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672789,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Instead of 100 mg, drug X should be given in divided doses.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the <strong>graph shown</strong>, the <strong>plasma concentration of drug X rises </strong>and then <strong>falls over time after administration. </strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. Given that the <strong>Cmax exceeds the minimum toxic concentration</strong>, <strong>reducing the dose </strong>would help to <strong>avoid toxic plasma levels of the drug</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Its Cmax is 20 &mu;g/dl</strong>: This is incorrect. <strong>Cmax refers </strong>to the <strong>peak plasma concentration </strong>of a <strong>drug after administration</strong>. In the graph, the Cmax appears to be higher than 20 &mu;g/dl, around 27 &mu;g/dl.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>AUC from the above graph reflects the rate of absorption of the drug</strong>: This is incorrect. The <strong>area under the curve </strong>(AUC) is related to the <strong>extent of absorption of the drug </strong>into the <strong>systemic circulation</strong>, not the rate. The rate of absorption is typically inferred from the Tmax and the steepness of the curve leading up to Cmax.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tmax for drug X is 7 hours</strong>: This is incorrect. <strong>Tmax </strong>is the <strong>time it takes for a drug </strong>to <strong>reach its maximum concentration </strong>in <strong>plasma</strong>. In the graph, the Tmax seems to be 4 hours, not 7 hours.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When a <strong>single dose of a drug </strong>results in a <strong>plasma concentration </strong>that <strong>exceeds the toxic threshold</strong>, the drug should be <strong>administered in divided doses </strong>to <strong>avoid toxicity</strong>.</span></span></span></span></p>",
      "correct_choice_id": 12414,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3117,
      "choices": [
        {
          "id": 12449,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></span></p>"
        },
        {
          "id": 12450,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rifampicin</span></span></span></span></p>"
        },
        {
          "id": 12451,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></span></span></p>"
        },
        {
          "id": 12452,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenobarbitone</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of fungal infection is being treated with multiple medications. He is also taking a drug known to interact with several other medications by inhibiting hepatic cytochrome P450 enzymes, leading to increased concentrations of co-administered drugs. Which of the following drugs is most likely to cause such an interaction by inhibiting cytochrome P450 enzymes?</span></span></span></span></p>",
      "unique_key": "Q8501861",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672793,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Ketoconazole </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ketoconazole </strong>is a known <strong>inhibitor of cytochrome P450 enzymes</strong>, particularly <strong>CYP3A4</strong>, and can <strong>increase plasma levels </strong>of <strong>drugs metabolized by these enzymes</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Rifampicin</strong>: Incorrect. Rifampicin is a known <strong>inducer of cytochrome P450 enzymes</strong>, which can decrease plasma levels of drugs metabolized by these enzymes.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phenytoin</strong>: Incorrect. Phenytoin is also an <strong>inducer of cytochrome P450 enzymes.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phenobarbitone</strong>: Incorrect. Phenobarbitone, like rifampicin and phenytoin, <strong>induces cytochrome P450 enzymes</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ketoconazole </strong>is an <strong>inhibitor of cytochrome P450 enzymes</strong>, which can <strong>lead to increased concentrations of drugs </strong>metabolized by these <strong>enzymes when administered concomitantly</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-153907.png\" style=\"height:518px; width:1000px\" /></span></span></span></span></p>",
      "correct_choice_id": 12449,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3391,
      "choices": [
        {
          "id": 13543,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial agonist</span></span></span></span></p>"
        },
        {
          "id": 13544,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Full agonist</span></span></span></span></p>"
        },
        {
          "id": 13545,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inverse agonist</span></span></span></span></p>"
        },
        {
          "id": 13546,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antagonist</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the provided drug response curve graph, what type of drug does the red-lined curve, represent?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/29/whatsapp-image-2023-09-29-at-120333.jpeg\" style=\"height:267px; width:300px\" /></p>",
      "unique_key": "Q8544486",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672803,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Inverse agonist</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-165152.png\" style=\"height:362px; width:600px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>red-lined curve </strong>in the provided figure <strong>represents an &quot;Inverse Agonist.&quot;</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This <strong>binds to the same receptor </strong>as an <strong>agonist but induces a pharmacological response opposite </strong>to that <strong>agonist</strong>. Therefore, the <strong>curve falls below the baseline</strong>, indicating a <strong>negative response </strong>or the <strong>reduction of activity below the basal level</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Partial Agonist</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This would <strong>produce a response</strong>, but its <strong>maximal effect </strong>is <strong>less than a full agonist</strong>, even when all <strong>receptors are occupied</strong>. The <strong>curve for a partial agonist </strong>would be <strong>above the baseline </strong>(indicating a positive response) but would not reach the same maximum as the full agonist.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Full Agonist</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This <strong>binds to the receptor </strong>and <strong>produces a maximum biological response. </strong>The curve would be expected to reach the highest point above the baseline in the graph, indicating the full efficacy of the drug.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Antagonist</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An <strong>antagonist </strong>would <strong>not produce any response itself</strong>; it would only <strong>block the effect of an agonist</strong>. The curve for a pure antagonist would be flat, aligning with the baseline because it does not activate the receptor nor produce a response on its own.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>red-lined curve </strong>that <strong>dips below the baseline </strong>represents an <strong>inverse agonist</strong>, which binds to a <strong>receptor and reduces its activity below the basal level</strong>.</span></span></span></span></p>",
      "correct_choice_id": 13545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3121,
      "choices": [
        {
          "id": 12465,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tmax</span></span></span></span></p>"
        },
        {
          "id": 12466,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Half life</span></span></span></span></p>"
        },
        {
          "id": 12467,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Area under the curve</span></span></span></span></p>"
        },
        {
          "id": 12468,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">None</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female with chronic pain is prescribed a new medication and advised to monitor its effects closely. She was educated on the pharmacokinetic profile of the medication using a plasma concentration versus time graph. Which of the following gives the rate of drug absorption in plasma concentration vs time graphs?&nbsp; </span></span></span></span></p>",
      "unique_key": "Q5809418",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672795,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans.&nbsp;A) Tmax </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug Absorption Curve</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-154446.png\" style=\"height:312px; width:600px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tmax </strong>is the <strong>time it takes for a drug to reach its maximum concentration in plasma</strong>. It <strong>reflects </strong>the <strong>rate of drug absorption</strong>; the <strong>shorter the Tmax</strong>, the <strong>faster the absorption rate.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Half-life</strong>: Incorrect. The <strong>half-life </strong>of a <strong>drug is the time required </strong>for the <strong>plasma concentration of the drug </strong>to <strong>reduce to half </strong>its <strong>maximum value</strong>, indicating the rate of drug elimination rather than absorption.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Area under the curve (AUC)</strong>: Incorrect. The <strong>AUC </strong>represents the <strong>drug&rsquo;s total exposure over time </strong>and is related to the <strong>extent of drug absorption</strong>, not the rate.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>None</strong>: Incorrect. <strong>Tmax </strong>is indeed a <strong>parameter that gives information </strong>about the <strong>rate of drug absorption</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tmax </strong>on a <strong>plasma concentration versus time graph </strong>provides <strong>information about the rate of absorption of a drug</strong>, with a <strong>shorter Tmax </strong>indicating <strong>faster absorption</strong>.</span></span></span></span></p>",
      "correct_choice_id": 12465,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3430,
      "choices": [
        {
          "id": 13699,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Naproxen is more efficacious than ibuprofen</span></span></span></span></p>"
        },
        {
          "id": 13700,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Naproxen is more potent than ibuprofen</span></span></span></span></p>"
        },
        {
          "id": 13701,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Naproxen is a full agonist, and ibuprofen is a partial agonist</span></span></span></span></p>"
        },
        {
          "id": 13702,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Naproxen is a better drug to take for pain relief than ibuprofen</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If 10 mg of naproxen produces the same analgesic response as 100 mg of ibuprofen, which of the following statements is correct? </span></span></span></span></p>",
      "unique_key": "Q9269650",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672809,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Naproxen is more potent than ibuprofen</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Potency</strong> is the <strong>amount of drug </strong>needed to <strong>produce a given effect.</strong> If a <strong>lower dose of naproxen </strong>produces the <strong>same analgesic response</strong> as a <strong>higher dose of ibuprofen,</strong> naproxen is considered more potent.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Naproxen is more efficacious than ibuprofen:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Efficacy </strong>refers to the <strong>maximum effect a drug can produce</strong>. Since the statement is comparing equal analgesic responses and not the maximum possible effects, we cannot determine efficacy from the given information.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Naproxen is a full agonist, and ibuprofen is a partial agonist:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Agonism </strong>relates to the <strong>ability of a drug to activate a receptor and produce a cellular response</strong>. Both naproxen and ibuprofen are full agonists at their respective targets, and their classification as full or partial agonists is not related to their potency or efficacy.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Naproxen is a better drug to take for pain relief than ibuprofen:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>&quot;better&quot; drug for pain relief </strong>depends on <strong>various factors</strong>, including <strong>efficacy, side effect profile</strong>, <strong>patient-specific factors</strong>, and more. Potency alone does not determine the overall appropriateness of a drug for pain relief.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Potency </strong>is determined by the <strong>amount of drug needed to produce a given effect</strong>, with <strong>more potent drugs </strong>requiring <strong>lower doses </strong>to achieve the <strong>same effect </strong>as compared with less potent drugs.</span></span></span></span></p>",
      "correct_choice_id": 13700,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65728,
      "choices": [
        {
          "id": 262077,
          "text": "<p><span style=\"font-size:12.0pt;\">Pioglitazone</span></p>"
        },
        {
          "id": 262078,
          "text": "<p><span style=\"font-size:12.0pt;\">Pramlintide</span></p>"
        },
        {
          "id": 262079,
          "text": "<p><span style=\"font-size:12.0pt;\">Glimepiride</span></p>"
        },
        {
          "id": 262080,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old patient with type 2 diabetes mellitus presents with unexplained nausea and bloating. The symptoms started after the initiation of a new medication. Which of the following anti-diabetic drugs is most likely associated with these symptoms? <i>(Twisted PYQ)</i></span></p>",
      "unique_key": "Q5099154",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673331,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Pramlintide</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pramlintide is an amylin analog used as an adjunctive treatment in diabetes. It slows gastric emptying and promotes satiety, which can lead to nausea and bloating as common side effects. These symptoms are often dose-dependent and tend to diminish with continued use.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other</strong> <strong>Options</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Pioglitazone:</strong> Incorrect as it is not associated with nausea or bloating. Its common side effects include weight gain, edema, and increased risk of heart failure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Glimepiride:</strong> Incorrect because it primarily causes hypoglycemia rather than gastrointestinal symptoms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D Metformin:</strong> Incorrect because although metformin causes gastrointestinal side effects, the most prominent symptom is diarrhea, not nausea and bloating specifically.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pramlintide commonly causes gastrointestinal symptoms like nausea and bloating due to its effect on gastric motility. Recognizing these side effects is crucial for appropriate management.</span></p>",
      "correct_choice_id": 262078,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44786,
      "choices": [
        {
          "id": 178791,
          "text": "<p><span style=\"font-size:12pt;\">Dapagliflozin</span></p>"
        },
        {
          "id": 178792,
          "text": "<p><span style=\"font-size:12pt;\">Pioglitazone</span></p>"
        },
        {
          "id": 178793,
          "text": "<p><span style=\"font-size:12pt;\">Sitagliptin</span></p>"
        },
        {
          "id": 178794,
          "text": "<p><span style=\"font-size:12pt;\">Metformin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following anti-diabetic drug is associated with increased risk of urinary tract infections? (</span>INICET May 2024)</p>",
      "unique_key": "Q4462466",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673327,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Dapagliflozin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. SGLT2 inhibitors work by promoting the excretion of glucose through the urine. This increased urinary glucose can create an environment that promotes the growth of bacteria, thereby increasing the risk of urinary tract infections. This class of drugs is well known for its association with UTIs and genital infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>B.</strong>&nbsp;<strong>Pioglitazone</strong>:&nbsp;Pioglitazone is a thiazolidinedione that improves insulin sensitivity. It is not associated with an increased risk of urinary tract infections. Common side effects include weight gain, edema, and an increased risk of heart failure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>C.</strong>&nbsp;<strong>Sitagliptin</strong>:&nbsp;Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing incretin levels, which in turn increase insulin secretion and decrease glucagon secretion. Sitagliptin is not commonly associated with an increased risk of urinary tract infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>D.</strong>&nbsp;<strong>Metformin</strong>:&nbsp;Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity. It is not associated with an increased risk of urinary tract infections. Common side effects of metformin include gastrointestinal disturbances such as diarrhea and abdominal discomfort.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In summary, dapagliflozin, an SGLT2 inhibitor, is associated with an increased risk of urinary tract infections due to its mechanism of increasing glucose excretion in the urine. This patient’s recurrent UTIs could be related to her use of dapagliflozin.</span></p>",
      "correct_choice_id": 178791,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3362,
      "choices": [
        {
          "id": 13427,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral </span></span></span></span></p>"
        },
        {
          "id": 13428,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intravenous</span></span></span></span></p>"
        },
        {
          "id": 13429,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sublingual </span></span></span></span></p>"
        },
        {
          "id": 13430,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subcutaneous</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man with chronic angina is prescribed a medication that is known to undergo significant hepatic first-pass metabolism. Which of the following routes of drug administration would not bypass the hepatic first-pass effect for this medication?</span></span></span></span></p>",
      "unique_key": "Q5236649",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672788,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Oral</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>oral route of administration </strong>subjects the <strong>drug to hepatic first-pass metabolism</strong>, where the <strong>drug is metabolized </strong>in the <strong>liver before reaching systemic circulation</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Intravenous</strong>: Incorrect. The <strong>intravenous route bypasses </strong>the <strong>hepatic first-pass effect </strong>by <strong>delivering the drug directly </strong>into the <strong>systemic circulation</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sublingual</strong>: Incorrect. The <strong>sublingual route bypasses </strong>the <strong>hepatic first-pass metabolism </strong>by allowing the drug to directly enter the systemic circulation via the oral mucosa.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Subcutaneous</strong>: Incorrect. The <strong>subcutaneous route bypasses </strong>the <strong>liver </strong>and allows the <strong>drug to slowly absorb </strong>into the <strong>systemic circulation</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>oral route </strong>of <strong>administration subjects drugs </strong>to <strong>hepatic first-pass metabolism</strong>, which can substantially <strong>reduce the bioavailability of drugs </strong>that are extensively <strong>metabolized by the liver</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs with high first pass metabolism include:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L: Lignocaine</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P: Propranolol</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G: Glyceryl tri nitrate (nitroglycerine)</span></span></span></span></p>",
      "correct_choice_id": 13427,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3416,
      "choices": [
        {
          "id": 13643,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase in water solubility</span></span></span></span></p>"
        },
        {
          "id": 13644,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase in lipid solubility</span></span></span></span></p>"
        },
        {
          "id": 13645,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nonionic to an active metabolite</span></span></span></span></p>"
        },
        {
          "id": 13646,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Makes it suitable to evaporate through skin surface</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the rationale behind xenobiotic metabolism by CYP enzymes?</span></span></span></span></p>",
      "unique_key": "Q2528108",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672807,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Increase in water solubility</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>major aim of metabolism </strong>of a <strong>drug is to make a drug water soluble.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Cytochrome P450 enzymes metabolize xenobiotics</strong> (foreign substances) primarily to <strong>increase their water solubility</strong>. Most <strong>xenobiotics are lipid-soluble</strong>, enabling them to <strong>cross cell membranes easily </strong>but making them <strong>difficult to excrete since the kidneys efficiently excrete water-soluble substances. </strong>By metabolizing these substances, CYP enzymes add or unmask polar functional groups, transforming them into more hydrophilic (water-soluble) compounds that can be readily excreted in urine or bile.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Increase in lipid solubility:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This option is incorrect. Increasing the lipid solubility of xenobiotics would be <strong>counterproductive, </strong>as it would make them more likely to <strong>accumulate in the body</strong>, potentially leading to toxicity.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Conversion from nonionic to an active metabolite:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While some <strong>CYP enzyme actions convert prodrugs</strong> to their <strong>active forms,</strong> this is <strong>not the primary rationale for xenobiotic metabolism.</strong> The main purpose is to enhance solubility for elimination, not necessarily activation.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Makes it suitable to evaporate through skin surface:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is incorrect. <strong>Xenobiotic metabolism by CYP enzymes</strong> is <strong>not</strong> primarily <strong>aimed at making substances evaporate through the skin. </strong>The skin is not a major route for eliminating most xenobiotics; the focus is on making them more water-soluble for renal and biliary excretion.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>primary role of cytochrome P450 enzymes</strong> in <strong>xenobiotic metabolism</strong> is to <strong>increase water solubility,</strong> thereby <strong>facilitating the excretion</strong> of these compounds through the <strong>kidneys or bile.</strong></span></span></span></span></p>",
      "correct_choice_id": 13643,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3433,
      "choices": [
        {
          "id": 13711,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Daily use of amphetamine causes norepinephrine to be released</span></span></span></span></p>"
        },
        {
          "id": 13712,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A disease that causes an increase in the activity of norepinephrine neurons</span></span></span></span></p>"
        },
        {
          "id": 13713,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Daily use of isoproterenol, a &beta;1 receptor agonist</span></span></span></span></p>"
        },
        {
          "id": 13714,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Daily use of propranolol, a &beta;1 receptor antagonist</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following would up-regulate postsynaptic &beta;1 adrenergic receptors?</span></span></span></span></p>",
      "unique_key": "Q4621682",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672810,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Daily use of propranolol, a &beta;1 receptor antagonist</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>regulation of receptor density </strong>or <strong>sensitivity on cell surfaces </strong>can be <strong>influenced by various factors</strong>, including the <strong>presence of agonists or antagonists</strong>, as well as <strong>changes in the levels of endogenous neurotransmitters. Up-regulation of receptors </strong>occurs when <strong>receptor activation is lower than normal</strong>, such as when the <strong>receptor is continuously exposed </strong>to an <strong>antagonist </strong>for that <strong>receptor. </strong>Down-regulation of receptor number occurs when receptor activation is greater than normal because of continuous exposure to an agonist.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chronic blockade of &beta;1 receptors </strong>with an <strong>antagonist </strong>such as <strong>propranolol </strong>can <strong>lead to up-regulation of those receptors</strong>. The body may respond to the inhibition of receptor activity by increasing the number of receptors to try to maintain normal sympathetic tone.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Daily use of amphetamine causes norepinephrine to be released:</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amphetamine increases </strong>the <strong>release of norepinephrine </strong>(NE), among other catecholamines. <strong>Chronic exposure</strong> to <strong>increased levels of neurotransmitters </strong>typically <strong>leads to a down-regulation of receptors</strong> to <strong>reduce sensitivity</strong>, not up-regulation.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>A disease that causes an increase in the activity of norepinephrine neurons:</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Similarly, a disease that causes <strong>sustained increases in norepinephrine activity</strong> would typically <strong>lead to down-regulation of adrenergic receptors as the body </strong>attempts to <strong>maintain homeostasis </strong>and <strong>reduce overstimulation.</strong></span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Daily use of isoproterenol, a &beta;1 receptor agonist:</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chronic exposure</strong> to an <strong>agonist like isoproterenol</strong> usually results in <strong>down-regulation of receptors</strong>. The nervous system tends to reduce the number of receptors in response to overstimulation to decrease sensitivity.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chronic exposure to a &beta;1 receptor antagonist </strong>like <strong>propranolol</strong> can <strong>lead to the up-regulation of postsynaptic &beta;1 adrenergic receptors</strong> as the body compensates for reduced receptor activation.</span></span></span></span></p>",
      "correct_choice_id": 13714,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3412,
      "choices": [
        {
          "id": 13627,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urinary excretion would be accelerated by the administration of NH4Cl, an acidifying agent</span></span></span></span></p>"
        },
        {
          "id": 13628,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urinary excretion would be accelerated by administration of NaHCO 3, an alkalinizing agent</span></span></span></span></p>"
        },
        {
          "id": 13629,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More of the drug would be ionized at blood pH than at stomach pH</span></span></span></span></p>"
        },
        {
          "id": 13630,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absorption of the drug would be faster from the stomach than from the small intestine</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A three-year-old child is brought to the emergency department having just ingested a large overdose of an antihistaminic drug. This drug is a weak base capable of entering most tissues including the brain. On physical examination the heart rate is 100/ minute, blood pressure is 110/60 mm Hg, and the respiratory rate is 20/ minute. In this case of poisoning:</span></span></span></span></p>",
      "unique_key": "Q1857717",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672805,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Urinary excretion would be accelerated by administration of NH4Cl, an acidifying agent</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Acidifying the urine </strong>with <strong>NH4Cl can increase the ionization of weak bases</strong>, such as the <strong>antihistaminic drug</strong>. <strong>Ionized drugs </strong>are not <strong>easily reabsorbed in the kidney tubules</strong>, enhancing elimination in the urine.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Alkalinizing the urine </strong>with <strong>NaHCO3 </strong>would <strong>reduce the ionization of the weak base</strong>, potentially decreasing its excretion.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect because the <strong>drug</strong>, <strong>being a weak base</strong>, is more <strong>ionized at an acidic pH </strong>(as in the stomach) than at the slightly alkaline blood pH.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect because <strong>weak bases </strong>are <strong>better absorbed in more alkaline environments</strong>, so absorption would generally be faster in the alkaline small intestine than in the acidic stomach.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To <strong>accelerate the urinary excretion </strong>of a <strong>weakly basic drug</strong>, <strong>acidify the urine</strong>, which <strong>promotes the ionization of the drug</strong>, thus <strong>reducing its reabsorption </strong>and <strong>increasing its elimination</strong>.</span></span></span></span></p>",
      "correct_choice_id": 13627,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7161,
      "choices": [
        {
          "id": 28612,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">New drug application is filed after phase 4</span></span></span></p>"
        },
        {
          "id": 28613,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 4 is also called post-marketing surveillance</span></span></span></p>"
        },
        {
          "id": 28614,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 3 are open label studies without any blinding</span></span></span></p>"
        },
        {
          "id": 28615,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 2 is done on healthy individuals</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is correct regarding clinical trials?&nbsp;</span></span></span>(INICET NOVEMBER 2022)</p>",
      "unique_key": "Q3394359",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673436,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Phase 4 is also called post-marketing surveillance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 4 clinical trials are also called post-marketing surveillance. This statement is correct. Phase 4 trials are conducted after a drug has been approved and marketed to monitor its long-term effectiveness and safety.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. New drug application is filed after phase 4:&nbsp;</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is incorrect. The New Drug Application (NDA) is filed after successful completion of Phase 3 clinical trials, not Phase 4. Phase 4 occurs after the drug has been approved and marketed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Phase 3 are open label studies without any blinding:&nbsp;</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is incorrect. Phase 3 clinical trials are typically randomized and double-blinded to eliminate bias and ensure robust results. Open label studies, where both the participants and investigators know which treatment is being administered, are less common in Phase 3 trials.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D. Phase 2 is done on healthy individuals:&nbsp;</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is incorrect. Phase 2 clinical trials are conducted on patients who have the condition that the drug is intended to treat. Phase 1 trials, on the other hand, are usually done on healthy volunteers to assess safety and dosage.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Educational Objective:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/01/screenshot-2023-12-01-181342.jpg\" style=\"height:717px; width:1000px\" /></span></span></p>",
      "correct_choice_id": 28613,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7029,
      "choices": [
        {
          "id": 28084,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Hydrocortisone</span></p>"
        },
        {
          "id": 28085,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Potassium binding resin</span></p>"
        },
        {
          "id": 28086,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Digoxin</span></p>"
        },
        {
          "id": 28087,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Calcium gluconate</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">An 18-month-old child with ambiguous genitalia presented to the hospital, his </span><span style=\"font-size:12.0pt;\">BP is 88/68 mm Hg</span><span style=\"font-size:12pt;\">, Serum K<sup>+</sup> is 6 mEq/L, serum sodium is 120 mEq/L. Patient was started on intravenous fluids. What additional specific therapy will you add?</span></p>",
      "unique_key": "Q9436180",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673319,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Hydrocortisone</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The presentation of an 18-month-old child with ambiguous genitalia, hypertension (BP is 88/68 mm Hg, which is low for this age), hyperkalemia (serum K of 6 mEq/L), and hyponatremia (serum sodium of 120 mEq/L) is suggestive of congenital adrenal hyperplasia (CAH), most likely due to 21-hydroxylase deficiency. This is a common form of CAH and can lead to a decrease in cortisol and aldosterone production, with an accompanying increase in adrenal androgens.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Given this clinical picture, the specific therapy to be added would include:</span></p><p style=\"text-align:justify;\">&nbsp;</p><ol><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Glucocorticoid Replacement:</strong> This is critical to suppress the overproduction of adrenal androgens. Hydrocortisone is commonly used, especially in pediatric patients, due to its short duration of action and lower impact on growth.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Mineralocorticoid Replacement:</strong> Fludrocortisone is usually added to manage the aldosterone deficiency, which is contributing to the hyperkalemia and hyponatremia.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Sodium Chloride Supplements:</strong> In some cases, especially in infants and young children, additional sodium chloride supplements may be necessary to manage hyponatremia.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Monitoring and Adjustment:</strong> Regular monitoring of electrolytes, blood pressure, and growth is necessary to adjust therapy accordingly.</span></p></li></ol><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B</strong>. <strong>Potassium Binding Resins:</strong> While these can be used to treat hyperkalemia, they do not address the underlying cause of the electrolyte imbalance in this scenario, which is likely due to aldosterone deficiency. Therefore, it would not be the first choice.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C</strong>. <strong>Digoxin:</strong> This is used primarily for heart failure and certain arrhythmias, not for the conditions described in this scenario.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D</strong>. <strong>Calcium Gluconate:</strong> This is used in the acute management of severe hyperkalemia to stabilize cardiac membranes. While it might be used in an emergency setting for life-threatening hyperkalemia, it does not address the underlying cause in this case and is not a long-term management strategy.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Therefore, the most appropriate addition to this patient's treatment regimen would be <strong>Hydrocortisone</strong> (option a), as it addresses the underlying cause of the symptoms in CAH. Additionally, monitoring and adjusting mineralocorticoid therapy (like fludrocortisone) would be important in the long-term management, especially given the electrolyte imbalances.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The most appropriate addition to this patient's treatment regimen would be Hydrocortisone, as it addresses the underlying cause of the symptoms in CAH. Additionally, monitoring and adjusting mineralocorticoid therapy (like fludrocortisone) would be important in the long-term management, especially given the electrolyte imbalances.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Reference: - KDT 8<sup>TH</sup>/314</strong></span></p>",
      "correct_choice_id": 28084,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7155,
      "choices": [
        {
          "id": 28588,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-1, B-3, C-2, D-4</span></span></span></span></span></p>"
        },
        {
          "id": 28589,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\">﻿﻿﻿<span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-4, B-1, C-3, D-2</span></span></span></span></span></p>"
        },
        {
          "id": 28590,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿A-2, B-4, C-1, D-3</span></span></span></span></span></p>"
        },
        {
          "id": 28591,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-3, B-2, C-4, D-1</span></span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-family:Helvetica\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following drugs in Column A with their contraindications in Column B? (INICET NOV 2022)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Helvetica\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/01/screenshot-2023-12-01-180006.jpg\" style=\"height:312px; width:700px\" /></span></span></span></p>",
      "unique_key": "Q8737841",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673433,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. <span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-4, B-1, C-3, D-2</span></strong></span></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphine is contraindicated in head injury due to the following reasons:</span></span></strong></span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes miosis and in patients with head injury who are in a comatose state, the progress of the patient after giving drugs is assessed by pupillary reaction. So, if the pupil already remains constricted due to morphine, the assessment of progress cannot be done.</span></span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphine leads to respiratory depression and if in the patients with head injury, if the respiratory rate is already depressed, it will get aggravated.</span></span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Respiratory depression will lead to accumulation of CO2, leading to vasodilatation and increased intracranial pressure.</span></span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone can cause QT prolongation and even precipitate Torsade de pointes.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vigabatrin is contraindicated in pregnancy as it is teratogenic.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Estrogen preparations are known to increase the risk of thromboembolism.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica\"><span style=\"font-family:Helvetica\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphine is contraindicated in head injury due to its effects on pupil size and respiratory depression. Amiodarone is associated with QT prolongation and potential arrhythmias. Vigabatrin is teratogenic and contraindicated in pregnancy. Estrogen increases the risk of thromboembolic events.</span></span></span></span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 28589,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65726,
      "choices": [
        {
          "id": 262069,
          "text": "<p><span style=\"font-size:12.0pt;\">SGLT2 inhibitors&nbsp;</span></p>"
        },
        {
          "id": 262070,
          "text": "<p><span style=\"font-size:12.0pt;\">DPP4 inhibitors&nbsp;</span></p>"
        },
        {
          "id": 262071,
          "text": "<p><span style=\"font-size:12.0pt;\">Sulfonylureas&nbsp;</span></p>"
        },
        {
          "id": 262072,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiazolidinediones</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old patient with newly diagnosed type 2 diabetes mellitus presents with an HbA1c of 8.2%. The patient has normal renal function but a strong family history of diabetic nephropathy. Which of the following drugs should be initiated first to prevent future renal complications? (Twisted PYQ)</span></p>",
      "unique_key": "Q9297415",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673317,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) SGLT2 inhibitors</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">SGLT2 inhibitors have demonstrated significant primary prevention of diabetic kidney disease.</span></li><li><span style=\"font-size:12.0pt;\">They reduce hyperfiltration and oxidative stress in the kidneys even before the onset of albuminuria.</span></li><li><span style=\"font-size:12.0pt;\">Recent guidelines recommend early initiation of SGLT2 inhibitors in high-risk patients for primary prevention of diabetic kidney disease.</span></li><li><span style=\"font-size:12.0pt;\">They also provide cardiovascular benefits and are weight neutral or promote weight loss.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. DPP4 inhibitors</strong>: While these are safe in renal impairment, they have not shown significant primary prevention benefits for diabetic kidney disease. Their effect on renal outcomes is neutral.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Sulfonylureas</strong>: These medications, while effective for glucose control, do not offer specific renoprotective benefits. They are associated with weight gain and hypoglycemia risk, which may indirectly impact renal outcomes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Thiazolidinediones</strong>: Although they may reduce albuminuria to some extent, their primary prevention benefits for diabetic kidney disease are not as robust as SGLT2 inhibitors. They are associated with fluid retention and weight gain.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Early intervention with medications that have proven renoprotective benefits is crucial in high-risk diabetic patients. SGLT2 inhibitors have emerged as first-line agents not only for glycemic control but also for primary prevention of diabetic kidney disease, especially in patients with risk factors for renal complications.</span></p>",
      "correct_choice_id": 262069,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6437,
      "choices": [
        {
          "id": 25717,
          "text": "<p><span style=\"font-size:12.0pt;\">Probenecid</span></p>"
        },
        {
          "id": 25718,
          "text": "<p><span style=\"font-size:12.0pt;\">Diazepam</span></p>"
        },
        {
          "id": 25719,
          "text": "<p><span style=\"font-size:12.0pt;\">Haloperidol</span></p>"
        },
        {
          "id": 25720,
          "text": "<p><span style=\"font-size:12.0pt;\">Sodium valproate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which is the drug used for refractory intractable rheumatic chorea?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p>",
      "unique_key": "Q1042326",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673328,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"margin-left:0px;\"><span style=\"font-size:14px;\"><strong>Ans. D) Sodium valproate</strong></span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\">Sodium valproate is the drug used for refractory intractable rheumatic chorea. It's an anticonvulsant medication that has proven effective in managing the involuntary movements associated with this condition. It works primarily by enhancing the effects of gamma-aminobutyric acid (GABA) in the brain, which helps reduce abnormal electrical activity.</span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\"><strong>Other Options:</strong></span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\"><strong>Option A. Probenecid:</strong> Probenecid is a medication used primarily to treat gout by reducing the levels of uric acid in the blood. It is not used for the treatment of rheumatic chorea.</span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\"><strong>Option B. Diazepam:</strong> Diazepam is a benzodiazepine used to treat anxiety, muscle spasms, and seizures. While it can provide muscle relaxation and sedation, it is not the drug of choice for managing refractory rheumatic chorea.</span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\"><strong>Option C. Haloperidol:</strong> Haloperidol is an antipsychotic medication that can be used in some movement disorders. While it has been used in chorea, it is not considered the optimal treatment for refractory intractable rheumatic chorea due to its side effect profile and efficacy compared to sodium valproate.</span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\"><strong>Educational Objective:</strong></span></p><p style=\"margin-left:0px;\">&nbsp;</p><p style=\"margin-left:0px;\"><span style=\"font-size:14px;\">Sodium valproate is the preferred drug for treating refractory intractable rheumatic chorea due to its efficacy in reducing involuntary movements by enhancing inhibitory neurotransmission in the brain. It has a better side effect profile for long-term management of this condition compared to other options.</span></p>",
      "correct_choice_id": 25720,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7153,
      "choices": [
        {
          "id": 28580,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This action can be reversed by phenylephrine.</span></span></span></span></span></p>"
        },
        {
          "id": 28581,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿It cannot be reversed by levallorphan.</span></span></span></span></span></p>"
        },
        {
          "id": 28582,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\">﻿﻿﻿<span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is caused by activation of the Edinger-Westphal nucleus.</span></span></span></span></span></p>"
        },
        {
          "id": 28583,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Tolerance develops to this adverse effect on long-term use.</span></span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of substance addiction is admitted to the hospital due to the overdose of the addictive substance. The patient has slow heart rate, respiratory depression, and low blood pressure. His ocular findings are shown below. Which of the following statements is true regarding this condition? (INICET NOV 2022)</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/750.jpg\" style=\"height:202px; width:300px\" /></span></span></span></span></span></p>",
      "unique_key": "Q2276188",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673432,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C.<span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is caused by activation of the Edinger-Westphal nucleus.</span></strong></span></span></span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The pupil is constricted in the given image and as the history describes the patient to be an addict, who is brought to the hospital in an intoxicated state. The clinical features like pin-point pupils, bradycardia, hypotension, respiratory depression suggests that this is a case of opioid intoxication.</span></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Opioid induced miosis:</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The pupillary constriction caused by opioids result due to the activation of the Edinger Westphal Nucleus. Therefore, topical use of opioids in the eye does not induce miosis. It will be seen only on systemic administration of opioids. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The miosis induced by opioids cannot be reversed by mydriatic drugs like phenylephrine or anticholinergic drugs. Rather it can be reversed by opioid antagonists like naloxone and levallorphan.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolerance does not develop to opioid induced miosis even on long term use. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. This action can be reversed by phenylephrine</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Phenylephrine is a mydriatic agent that causes dilation of the pupil by stimulating alpha-1 adrenergic receptors. It would not reverse opioid-induced miosis, which is due to central nervous system effects rather than direct effects on the iris muscles.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. It cannot be reversed by levallorphan</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Levallorphan is an opioid antagonist that can reverse the effects of opioid toxicity, including miosis. Therefore, this statement is incorrect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D. Tolerance develops to this adverse effect on long-term use:</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tolerance to opioid-induced miosis does not typically develop, even with long-term use of opioids. Therefore, this statement is incorrect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Opioid-induced miosis is caused by activation of the Edinger-Westphal nucleus, and it is a characteristic sign of opioid intoxication. This effect cannot be reversed by phenylephrine, and tolerance does not develop to this effect with long-term opioid use. Opioid antagonists like naloxone and levallorphan can reverse the miosis caused by opioid overdose</span></span></span></p>",
      "correct_choice_id": 28582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3415,
      "choices": [
        {
          "id": 13639,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Case control study</span></span></span></span></p>"
        },
        {
          "id": 13640,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase II Randomized control trials</span></span></span></span></p>"
        },
        {
          "id": 13641,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase I trial</span></span></span></span></p>"
        },
        {
          "id": 13642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase IV Randomized control trials</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following trials can be performed to determine the maximal tolerated dose (MTD) of a drug? </span></span></span></span></p>",
      "unique_key": "Q6814552",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672806,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Phase I trial</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase I trials</strong> are the <strong>first stage of testing in human subjects</strong>. They are primarily concerned with safety and, as such, are <strong>designed to find the MTD of a drug</strong>. These trials start with a <strong>low dose of the drug</strong> and gradually <strong>increase the dose with new cohorts of patients</strong> until unacceptable side effects appear, thus establishing the MTD.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Case Control Study:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Case control studies are <strong>retrospective analyses</strong> that <strong>compare patients with a specific outcome</strong> (e.g., those with an adverse reaction to a drug) to <strong>those without that outcome. </strong>They are not designed to determine MTD but rather to investigate potential causes or associations after the fact.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Phase II Randomized Control Trials:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase II trials </strong>are designed to <strong>assess efficacy </strong>and further <strong>evaluate the safety of a drug</strong>, usually in a <strong>larger group of patients than in Phase I.</strong> While Phase II trials do gather more safety data and can refine the understanding of a drug&#39;s MTD, their primary goal is not to determine MTD but to establish preliminary evidence of therapeutic effect.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phase IV Randomized Control Trials:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Phase IV trials </strong>occur <strong>after a drug has been approved for market.</strong> They involve <strong>post-marketing surveillance</strong> to <strong>detect rare adverse events </strong>and to <strong>collect information on long-term efficacy and safety</strong>. These trials are not designed to determine MTD but to monitor the drug&#39;s performance in a real-world setting across a broad population.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>maximal tolerated dose </strong>of a <strong>drug is primarily determined during Phase I clinical trials, </strong>where <strong>safety is the main focu</strong>s, and dosing is carefully controlled to observe the emergence of adverse effects, thereby establishing the MTD.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/whatsapp-image-2024-05-10-at-54113-pm.jpeg\" style=\"height:1053px; width:1000px\" /></span></span></span></span></p>",
      "correct_choice_id": 13641,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57295,
      "choices": [
        {
          "id": 228557,
          "text": "<p><span style=\"font-size:12pt;\">It is an Equal Mixture of Local Anesthetics</span></p>"
        },
        {
          "id": 228558,
          "text": "<p><span style=\"font-size:12pt;\">It contains lignocaine and ropivacaine in a ratio of 50 percent each</span></p>"
        },
        {
          "id": 228559,
          "text": "<p><span style=\"font-size:12pt;\">Excessive use can result in methemoglobinemia</span></p>"
        },
        {
          "id": 228560,
          "text": "<p><span style=\"font-size:12pt;\">5 ml of 5 percent mixture contains 50 mg lignocaine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following statements regarding the patch used in the given figure is correct? (NEET PG 2024)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/16/screenshot-2024-09-16-184820.jpg\" alt=\"\" width=\"400\" height=\"272\"></span></p>",
      "unique_key": "Q6801604",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673329,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Excessive use can result in methemoglobinemia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The patch in the image is an EMLA patch, which stands for Eutectic Mixture of Local Anesthetics. It is commonly used to numb the skin before procedures like needle insertions. The EMLA patch contains a mixture of two local anesthetics: lignocaine (also known as lidocaine) and prilocaine, each at a concentration of 2.5%.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">One of the known side effects of prilocaine, especially when used in excessive amounts, is the risk of methemoglobinemia. This condition occurs when hemoglobin is converted to methemoglobin, which cannot effectively release oxygen to body tissues. Although the risk is generally low, it can be significant in infants and other at-risk populations.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. It is an Equal Mixture of Local Anesthetics:</strong> This statement is misleading. While the mixture contains equal concentrations of lignocaine and prilocaine (2.5% each), the term \"eutectic\" is key, indicating that the two anesthetics lower each other's melting points when combined, creating a mixture that is liquid at room temperature. The emphasis should be on the \"eutectic\" nature rather than just being an \"equal mixture.\"</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. It contains lignocaine and ropivacaine in a ratio of 50 percent each:</strong> This is incorrect because the EMLA patch contains lignocaine and prilocaine, not ropivacaine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. 5 ml of 5 percent mixture contains 50 mg lignocaine:</strong> This calculation is incorrect. A 5% solution means 5 g of the drug is present in 100 ml of solution, which translates to 50 mg/ml. Therefore, 5 ml of the mixture would contain 250 mg of lignocaine, not 50 mg.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Prilocaine, one of the components of the EMLA patch, can cause methemoglobinemia, especially when used in excessive amounts or in vulnerable populations like infants.</span></p>",
      "correct_choice_id": 228559,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65729,
      "choices": [
        {
          "id": 262081,
          "text": "<p><span style=\"font-size:12.0pt;\">Aztreonam</span></p>"
        },
        {
          "id": 262082,
          "text": "<p><span style=\"font-size:12.0pt;\">Vancomycin</span></p>"
        },
        {
          "id": 262083,
          "text": "<p><span style=\"font-size:12.0pt;\">Ceftriaxone</span></p>"
        },
        {
          "id": 262084,
          "text": "<p><span style=\"font-size:12.0pt;\">Piperacillin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old patient with a known allergy to penicillin presents with a gram-negative bacteremia caused by <i>Pseudomonas aeruginosa</i>. The physician wants to prescribe an antibiotic that is safe for a patient with a penicillin allergy. Which of the following drugs is the most appropriate choice? <i>(Twisted PYQ)</i></span></p>",
      "unique_key": "Q2765289",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673318,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Aztreonam</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Aztreonam is a monobactam antibiotic that is specifically effective against gram-negative bacteria, including Pseudomonas aeruginosa. It is structurally distinct from penicillins and cephalosporins, making it a safe option for patients with penicillin allergies. Aztreonam does not cover gram-positive bacteria, but for this scenario involving Pseudomonas aeruginosa (a gram-negative organism), it is highly effective.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Vancomycin:</strong> Incorrect because vancomycin is effective only against gram-positive bacteria and would not treat a gram-negative infection like Pseudomonas aeruginosa.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C Ceftriaxone:</strong> Incorrect because, while ceftriaxone can be used for certain gram-negative infections, caution is advised in patients with severe penicillin allergies due to the risk of cross-reactivity. Furthermore, ceftriaxone has limited activity against Pseudomonas aeruginosa.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Piperacillin:</strong> Incorrect because it is a penicillin derivative and contraindicated in patients with penicillin allergies due to a high risk of allergic reactions.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Aztreonam is a safe and effective option for treating gram-negative infections in patients with penicillin allergies, particularly when dealing with Pseudomonas aeruginosa</span></p>",
      "correct_choice_id": 262081,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6944,
      "choices": [
        {
          "id": 27744,
          "text": "<p><span style=\"font-size:12.0pt;\">Cimetidine</span></p>"
        },
        {
          "id": 27745,
          "text": "<p><span style=\"font-size:12.0pt;\">Carbamazepine</span></p>"
        },
        {
          "id": 27746,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid</span></p>"
        },
        {
          "id": 27747,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs does not increase the risk of bleeding in patients undergoing warfarin therapy?</span></p>",
      "unique_key": "Q6679185",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673322,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Carbamazepine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Warfarin is an anticoagulant that is metabolized primarily by the CYP2C9 enzyme. The risk of bleeding with warfarin therapy is influenced by drugs that either inhibit or induce the metabolism of warfarin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Carbamazepine, is an enzyme inducer. It induces CYP450 enzymes, including CYP2C9, which increases the metabolism of warfarin, leading to reduced plasma warfarin levels and a decreased anticoagulant effect. Therefore, carbamazepine does not increase the risk of bleeding; instead, it can reduce the effectiveness of warfarin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Cimetidine:&nbsp;</strong>Cimetidine is a known inhibitor of the CYP450 enzymes, including CYP2C9. By inhibiting this enzyme, cimetidine reduces the metabolism of warfarin, leading to higher plasma concentrations of warfarin and an increased risk of bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Isoniazid:&nbsp;</strong>Isoniazid is an inhibitor of several CYP450 enzymes, including CYP2C9. This inhibition can lead to decreased metabolism of warfarin, increased plasma warfarin levels, and a higher risk of bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Amiodarone:&nbsp;</strong>Amiodarone is a potent inhibitor of CYP2C9. It reduces the metabolism of warfarin, resulting in elevated levels of warfarin in the blood and an increased risk of bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Warfarin is mainly metabolized by the CYP2C9 enzyme. Drugs like Cimetidine, Isoniazid, Amiodarone, Clopidogrel, Ketoconazole, Verapamil etc inhibit the enzyme, thus reducing the metabolism of warfarin. This increases the plasma concentration of Warfarin and leads to increased risk of bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Carbamazepine is an enzyme inducer and increases the metabolism of warfarin leading to decrease in effect of warfarin.</span></p>",
      "correct_choice_id": 27745,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3379,
      "choices": [
        {
          "id": 13495,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has low glomerular filtration</span></span></span></span></p>"
        },
        {
          "id": 13496,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has less drug interactions</span></span></span></span></p>"
        },
        {
          "id": 13497,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is likely to have a higher volume of distribution</span></span></span></span></p>"
        },
        {
          "id": 13498,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be easily filtered by dialysis</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old woman with chronic kidney disease and hypertension is admitted to the hospital for management of medication-related complications. She is currently on multiple medications, including one that is known to have high plasma protein binding. The medical team is concerned about the potential for drug interactions and the efficacy of hemodialysis in removing this drug in the event of an overdose. A discussion ensues regarding the pharmacokinetic characteristics of drugs with high plasma protein binding.Regarding the pharmacokinetics of drugs with high plasma protein binding, which of the following statements is most accurate?</span></span></span></span></p>",
      "unique_key": "Q4761575",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672797,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) It has low glomerular filtration</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Drugs </strong>that are <strong>highly bound to plasma proteins </strong>are <strong>not freely filtered through the glomerulus</strong>, resulting in <strong>lower rates of glomerular filtration</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: It has less drug interactions</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect. <strong>Drugs with high plasma protein binding </strong>are more likely to have <strong>drug-drug interactions</strong>, particularly those involving displacement from binding sites.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: It is likely to have a higher volume of distribution</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect. A <strong>high plasma protein binding </strong>typically <strong>correlates with a lower volume of distribution </strong>because the drug tends to remain within the vascular compartment.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: It can be easily filtered by dialysis</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect. <strong>Drugs </strong>with <strong>high plasma protein binding </strong>are <strong>not easily removed </strong>by <strong>hemodialysis </strong>due to their <strong>strong affinity for plasma proteins</strong>, which keeps them within the bloodstream.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Drugs with high plasma protein binding </strong>have <strong>low glomerular filtration rates </strong>because they are largely restricted to the <strong>vascular compartment </strong>and <strong>not freely filtered by the kidneys</strong>.</span></span></span></span></p>",
      "correct_choice_id": 13495,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3378,
      "choices": [
        {
          "id": 13491,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graded Dose Response Curve</span></span></span></span></p>"
        },
        {
          "id": 13492,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quantal Dose response Curve</span></span></span></span></p>"
        },
        {
          "id": 13493,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Log Dose Response Curve</span></span></span></span></p>"
        },
        {
          "id": 13494,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therapeutic Index</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of hypertension is seen in the clinic for blood pressure management. The patient reports varying levels of blood pressure control, and the physician suspects that this might be due to individual variations in drug response. In discussing this issue with a group of medical students, the physician asks - variation in sensitivity of response to different doses of a drug in different individuals is obtained from?</span></span></span></span></p>",
      "unique_key": "Q4665198",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672796,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Quantal Dose response curve</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Variation in sensitivity </strong>of <strong>response to different doses of a drug</strong> in <strong>different individuals</strong> is best represented by a Quantal Dose Response Curve.&nbsp;</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This <strong>curve is used to show the variation in response </strong>to a <strong>drug in a population</strong>. It <strong>plots the percentage </strong>of a <strong>population </strong>that <strong>shows a specified response </strong>at progressively <strong>increasing doses</strong>. This <strong>type of curve </strong>is particularly <strong>useful in understanding the variability of drug response </strong>in <strong>different individuals</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Graded Dose Response Curve:</strong> This <strong>type of curve </strong>shows the <strong>relationship between the dose of a drug </strong>and the <strong>gradation of the effect </strong>(response) in a <strong>single individual or tissue</strong>. It doesn&rsquo;t directly reflect variations among different individuals.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Log Dose Response Curve:</strong> This is a <strong>variation of the graded dose-response curve</strong>, where the <strong>dose is plotted on a logarithmic scale</strong>. This format can make it easier to see the relationship between dose and response, especially over a wide range of doses, but it does not specifically address the variation in sensitivity among different individuals.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Therapeutic Index:</strong> The therapeutic index is a <strong>ratio that compares the toxic dose </strong>to the <strong>therapeutic dose of a drug</strong>, used to assess its safety. While it provides information about the safety margin of the drug, it does not directly show the variation in sensitivity to the drug among different individuals.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Quantal Dose Response Curve </strong>is used to <strong>determine the variation </strong>in <strong>sensitivity to different doses </strong>of a <strong>drug among different individuals in a population</strong>.</span></span></span></span></p>",
      "correct_choice_id": 13492,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6946,
      "choices": [
        {
          "id": 27752,
          "text": "<p><span style=\"font-size:12.0pt;\">Dexamethasone</span></p>"
        },
        {
          "id": 27753,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 27754,
          "text": "<p><span style=\"font-size:12.0pt;\">Diltiazem</span></p>"
        },
        {
          "id": 27755,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetazolamide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is used in acute mountain sickness?</span></p>",
      "unique_key": "Q1634633",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673324,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D. Acetazolamide</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Acetazolamide is the drug of choice for acute mountain sickness. Rapid ascent to high altitudes can lead to the development of headache, nausea, vomiting, dizziness, breathlessness etc. The underlying cause that has been implicated in its causation is cerebral edema. The low PO2 at high altitude causes arteriolar dilation, and if cerebral autoregulation does not compensate, there is an increase in capillary pressure that favors increased transudation of fluid into brain tissue leading to cerebral edema.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Acetazolamide is a carbonic anhydrase inhibitor that leads to metabolic acidosis, which in turn stimulates hyperventilation, leading to CO2 washout, and it helps in reducing the formation of CSF.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Dexamethasone:&nbsp;</strong>Dexamethasone is a corticosteroid and can be used as a treatment for cerebral edema and severe cases of AMS. However, it is not the first-line drug of choice for general AMS prevention or mild cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Digoxin:&nbsp;</strong>Digoxin is a cardiac glycoside used primarily for heart conditions such as atrial fibrillation and heart failure. It has no role in the prevention or treatment of acute mountain sickness.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Diltiazem:&nbsp;</strong>Diltiazem is a calcium channel blocker used for treating hypertension and angina. It is not used in the management of acute mountain sickness.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Acetazolamide is the drug of choice for acute mountain sickness because it induces metabolic acidosis and stimulates hyperventilation, helping to improve oxygenation and reduce cerebral edema.</span></p>",
      "correct_choice_id": 27755,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3089,
      "choices": [
        {
          "id": 12339,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenaline and Isoprenaline</span></span></span></span></p>"
        },
        {
          "id": 12340,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Histamine and adrenaline</span></span></span></span></p>"
        },
        {
          "id": 12341,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isoprenaline and propranolol</span></span></span></span></p>"
        },
        {
          "id": 12342,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the above</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following set of drugs can be considered as physiological antagonists?</span></span></span></span></p>",
      "unique_key": "Q8669568",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672785,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans.&nbsp;B) Histamine and adrenaline</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Physiological antagonism </strong>occurs when <strong>two drugs produce opposing physiological effects </strong>through <strong>different receptors </strong>or <strong>mechanisms</strong>, which can <strong>result in a net effect of zero </strong>or <strong>reduced effect</strong>. This is in contrast to pharmacological antagonism, where one drug directly blocks the receptor site of another.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Histamine </strong>typically <strong>causes bronchoconstriction </strong>by <strong>acting on H1 receptors</strong>, while <strong>adrenaline causes bronchodilation </strong>by <strong>acting on &beta;2 receptors</strong>. Because they act on different receptors to produce opposing effects, they can be considered physiological antagonists.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Adrenaline and Isoprenaline</strong>: These are <strong>both sympathomimetic agents </strong>that <strong>act on adrenergic receptors</strong>, not physiological antagonists.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Isoprenaline and Propranolol</strong>: <strong>Isoprenaline </strong>is an <strong>agonist of &beta;-adrenergic receptors</strong>, while propranolol is a &beta;-adrenergic receptor antagonist. They are pharmacological antagonists because they bind to the same receptor with opposing actions.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>All the above</strong>: This option is incorrect because it <strong>includes both physiological antagonists </strong>(histamine and adrenaline) and <strong>pharmacological antagonists </strong>(isoprenaline and propranolol).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Physiological antagonists </strong>are those that <strong>produce opposite action </strong>by <strong>acting on different receptors </strong>eg. <strong>Histamine and adrenaline</strong></span></span></span></span></p>",
      "correct_choice_id": 12340,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56117,
      "choices": [
        {
          "id": 223893,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">CYP3A4; Simvastatin</span></span></span></span></span></p>"
        },
        {
          "id": 223894,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">CYP2E1; Acetaminophen</span></span></span></span></span></p>"
        },
        {
          "id": 223895,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">CYP2C9; Carbamazepine</span></span></span></span></span></p>"
        },
        {
          "id": 223896,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">CYP2D6; Metoprolol</span></span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 45-year-old female with a history of epilepsy and type 2 diabetes mellitus presents to the clinic for a follow-up visit. She is currently on carbamazepine for seizure control and metformin for diabetes management. The physician considers starting her on warfarin for a newly diagnosed deep vein thrombosis (DVT). The physician is concerned about potential drug interactions involving cytochrome P450 (CYP) isoforms. Which of the following CYP isoforms is primarily responsible for the metabolism of warfarin, and which substrate is most likely to have a clinically significant interaction with warfarin in this patient?</span></span></span></p>",
      "unique_key": "Q5523091",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672798,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. C) CYP2C9; Carbamazepine</span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Warfarin is primarily metabolized by CYP2C9. Carbamazepine is an inducer of CYP2C9, which can lead to increased metabolism of warfarin and reduced anticoagulant effect, making it a clinically significant interaction.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Other Options: </span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option A. CYP3A4; Simvastatin:</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;While CYP3A4 is a major enzyme that metabolizes many drugs, warfarin is not primarily metabolized by CYP3A4. Simvastatin is a CYP3A4 substrate, but this is not relevant to warfarin metabolism.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option B. CYP2E1; Acetaminophen:</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;CYP2E1 is involved in the metabolism of acetaminophen, but it is not relevant to warfarin metabolism.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D. CYP2D6; Metoprolol:</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;CYP2D6 metabolizes many drugs, including metoprolol, but warfarin is not primarily metabolized by CYP2D6.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Educational Objective:</span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Understand that warfarin is primarily metabolized by the CYP2C9 enzyme and that carbamazepine, a known inducer of CYP2C9, can increase the metabolism of warfarin, potentially reducing its anticoagulant effect and necessitating dose adjustments.</span></span></span></span></span></p>",
      "correct_choice_id": 223895,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6497,
      "choices": [
        {
          "id": 25957,
          "text": "<p><span style=\"font-size:12.0pt;\">Ofloxacin</span></p>"
        },
        {
          "id": 25958,
          "text": "<p><span style=\"font-size:12.0pt;\">Levofloxacin</span></p>"
        },
        {
          "id": 25959,
          "text": "<p><span style=\"font-size:12.0pt;\">Pefloxacin</span></p>"
        },
        {
          "id": 25960,
          "text": "<p><span style=\"font-size:12.0pt;\">Lomefloxacin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old man with chronic liver disease is experiencing recurrent urinary tract infections. His healthcare team is considering various antibiotics, including fluoroquinolones, to treat the infection. Which of the following fluoroquinolones is not recommended for use in patients with liver disease? (NEET PG 2020)</span></p>",
      "unique_key": "Q7850447",
      "question_audio": null,
      "question_video": null,
      "map_id": 33673320,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Pefloxacin</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Pefloxacin is a fluoroquinolone antibiotic that is primarily eliminated by the liver. In patients with liver disease, pefloxacin can accumulate in the body and cause hepatotoxicity. Therefore, it is not recommended for use in patients with liver disease or hepatic impairment.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Ofloxacin</strong>: Ofloxacin is a fluoroquinolone antibiotic that is eliminated by both the liver and the kidneys. It can be used with caution in patients with liver disease, provided the dosage is adjusted according to hepatic function.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Levofloxacin</strong>: Levofloxacin is another fluoroquinolone that is eliminated by both the liver and kidneys. It is generally considered safe for use in patients with liver disease, with appropriate dose adjustments based on hepatic function.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Lomefloxacin</strong>: Lomefloxacin is also eliminated by both the liver and kidneys and can be used in patients with liver disease, provided that dosage adjustments are made.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Fluoroquinolones that are safe in renal failure, avoided in liver failure and not effective in UTI include:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">P: Pefloxacin</span></li><li><span style=\"font-size:12.0pt;\">M: Moxifloxacin</span></li><li><span style=\"font-size:12.0pt;\">T: Trovafloxacin</span></li></ul>",
      "correct_choice_id": 25959,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3063,
      "choices": [
        {
          "id": 12237,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Is the same as bioavailability</span></span></span></span></p>"
        },
        {
          "id": 12238,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is directly proportional to clearance</span></span></span></span></p>"
        },
        {
          "id": 12239,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is inversely proportional to volume of distribution</span></span></span></span></p>"
        },
        {
          "id": 12240,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is constant for the drugs eliminated by first order kinetics</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What of the following is true about plasma half-life?</span></span></span></span></p>",
      "unique_key": "Q9724921",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672811,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) It is constant for the drugs eliminated by first order kinetics</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is the <strong>correct statement</strong>. For <strong>drugs </strong>that are <strong>eliminated from the body through first-order kinetics</strong>, the <strong>plasma half-life remains constant</strong>. In <strong>first-order kinetics</strong>, a <strong>constant fraction of the drug </strong>is <strong>metabolized per unit time</strong>, regardless of the <strong>total drug concentration</strong>. This means that the <strong>half-life</strong>, which is the <strong>time it takes for the drug concentration </strong>in the <strong>blood to decrease by half</strong>, remains <strong>consistent over time</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>zero order kinetics</strong>, <strong>half-life is directly proportional </strong>to <strong>plasma concentration</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the correct answer is: <strong>It is constant for the drugs eliminated by first order kinetics.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Is the same as bioavailability:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is incorrect. <strong>Bioavailability </strong>refers to the <strong>fraction of an administered dose </strong>of a <strong>drug that reaches the systemic circulation </strong>in its <strong>active form</strong>. In contrast, plasma half-life is the time required for the concentration of the drug in the plasma to reduce to half its original value. These are distinct pharmacokinetic properties.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is directly proportional to clearance: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is incorrect. <strong>Plasma half-life is inversely related to clearance</strong>. Clearance is the rate at which a drug is removed from the body. If a drug is cleared quickly from the body (high clearance), its plasma half-life will be shorter, and vice versa.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. It is inversely proportional to volume of distribution: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is actually a misunderstanding. <strong>Plasma half-life is not solely dependent on the volume of distribution</strong>. The relationship between half-life, volume of distribution, and clearance is given by the formula: half-life = (0.693 &times; volume of distribution) / clearance. Thus, half-life is directly proportional to the volume of distribution and inversely proportional to clearance.&nbsp;</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u></span></span></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For <strong>drugs eliminated via first-order kinetics</strong>, the <strong>plasma half-life remains constant</strong> because a <strong>fixed percentage of the drug </strong>is <strong>metabolized per unit time</strong>, regardless of the drug&#39;s concentration in the plasma.</span></span></span></span></p>",
      "correct_choice_id": 12240,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13838,
      "choices": [
        {
          "id": 55313,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High plasma protein binding</span></span></span></span></p>"
        },
        {
          "id": 55314,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low ionization at physiological pH values</span></span></span></span></p>"
        },
        {
          "id": 55315,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High lipid solubility</span></span></span></span></p>"
        },
        {
          "id": 55316,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High tissue binding</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following factors tend to increase the volume of distribution of a drug EXCEPT:</span></span></p>",
      "unique_key": "Q3628712",
      "question_audio": null,
      "question_video": null,
      "map_id": 33672783,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) High plasma protein binding.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When a <strong>drug binds</strong> extensively to <strong>plasma proteins,</strong> such as <strong>albumin</strong>, its ability to <strong>leave the bloodstream </strong>and <strong>distribute</strong> into<strong> other tissues is reduced</strong>. This <strong>leads to a lower Vd </strong>because a <strong>greater proportion of the drug</strong> remains confined to the <strong>plasma.</strong></span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri, sans-serif\"><span style=\"font-size:16px\"><strong><u>Other Options:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Low ionization at physiological pH values:&nbsp;</span></span></strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs that are <strong>less ionized </strong>at<strong> physiological pH</strong> can<strong> more </strong>readily <strong>cross cell</strong> <strong>membranes</strong> since <strong>non-ionized forms</strong> are generally<strong> more lipid-soluble.</strong> This allows the <strong>drug to distribute more widely</strong> into <strong>various</strong> <strong>tissues</strong>, including those <strong>beyond the vascular compartment</strong>, thus <strong>increasing the Vd.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. High lipid solubility:&nbsp;</span></span></strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lipid-soluble drugs</strong> can<strong> cross cell membranes</strong> more<strong> easily </strong>and can <strong>accumulate in fatty tissues</strong>. This property can <strong>lead to a larger Vd</strong> because the <strong>drug can be distributed more extensively into body tissues,</strong> particularly <strong>fat stores</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. High tissue binding:&nbsp;</span></span></strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When a drug has a<strong> high affinity </strong>for<strong> tissue binding sites</strong>, it will be <strong>sequestered in these peripheral</strong> <strong>compartments rather than </strong>remaining in the<strong> bloodstream</strong>. This <strong>sequestration in tissues increases the Vd </strong>as the drug is <strong>stored</strong> <strong>outside of the vascular system.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u></strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While<strong> high lipid solubility,</strong> <strong>low ionization</strong>, and<strong> high tissue binding increase</strong> a <strong>drug&#39;s volume of distribution</strong>, <strong>high plasma protein</strong> <strong>binding</strong> generally<strong> decreases it.</strong></span></span></p>",
      "correct_choice_id": 55313,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}